<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAW</journal-id>
<journal-id journal-id-type="hwp">sptaw</journal-id>
<journal-title>Therapeutic Advances in Drug Safety</journal-title>
<issn pub-type="ppub">2042-0986</issn>
<issn pub-type="epub">2042-0994</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/2042098611433192</article-id>
<article-id pub-id-type="publisher-id">10.1177_2042098611433192</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Antiepileptic drugs in women with epilepsy during pregnancy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Gedzelman</surname><given-names>Evan</given-names></name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Meador</surname><given-names>Kimford J.</given-names></name>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-2042098611433192">Kimford J. Meador, MD Department of Neurology, Emory University School of Medicine, Woodruff Memorial Research Building, 101 Woodruff Circle, Suite 6000, Atlanta, GA 30322, USA <email>kimford.meador@emory.edu</email></corresp>
<corresp id="corresp2-2042098611433192">Evan Gedzelman, MD Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>3</volume>
<issue>2</issue>
<fpage>71</fpage>
<lpage>87</lpage>
<permissions>
<copyright-statement>© The Author(s), 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Prescribing antiepileptic drugs (AEDs) in pregnancy is a challenge to the clinician. A multitude of questions arise that must be addressed even prior to conception. In women with proven epilepsy, it may be dangerous to stop or even change the AED regimen during pregnancy. Changes could lead to injury or death in both the mother and the fetus. In the rare cases when discontinuing an AED is plausible, it should be done methodically in consultation with the physician prior to conception. Most women with epilepsy are consigned to continue their AEDs before, during and after pregnancy. The metabolism of AEDs may change drastically during pregnancy. These changes must be addressed by the clinician. Drug levels should be monitored consistently during pregnancy. The risks to the fetus must be delineated in terms of side effects from specific drugs as well as risks from the seizure disorder itself. Many AEDs have well known teratogenic effects, and these must be elucidated to the mother. There are risks (theoretical and evidence based) for obstetrical complications, poor neonatal outcomes, congenital malformations and even cognitive effects on the child later in life. These risks are addressed in this article with respect to individual AEDs. Recommendations include but are not limited to preconception counseling, taking folate pre and post conception, prescribing the most effective AED while minimizing risks, and avoiding polytherapy and valproate if possible.</p>
</abstract>
<kwd-group>
<kwd>antiepileptic drugs</kwd>
<kwd>congenital malformations</kwd>
<kwd>epilepsy</kwd>
<kwd>neurodevelopment</kwd>
<kwd>pregnancy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-2042098611433192" sec-type="intro">
<title>Introduction</title>
<p>Epilepsy is defined by the presence of recurrent, unprovoked seizures. The typical treatment is a daily, long-term antiepileptic drug (AED) regimen. People with epilepsy expect to participate fully in life experiences, including childbearing, as the majority of them have well controlled seizures, and are otherwise healthy [<xref ref-type="bibr" rid="bibr28-2042098611433192">Harden <italic>et al</italic>. 2009b</xref>]. According to the US Department of Health’s recent estimates of the US population and the known prevalence of epilepsy, approximately half a million women with epilepsy (WWE) are of childbearing age [<xref ref-type="bibr" rid="bibr31-2042098611433192">Hirtz <italic>et al</italic>. 2007</xref>]. It has been estimated that three to five births per 1000 will be to WWE [<xref ref-type="bibr" rid="bibr108-2042098611433192">Yerby, 2000</xref>]. <italic>In utero</italic> exposure to some AEDs is associated with an increased risk of major congenital malformations (MCMs), possible obstetrical complications, possible neonatal complications, impaired behavioral development, and impaired cognitive development in the child. These risks must be weighed against the risk of recurrent seizures in the mother and the complications that could come as a result of changing or stopping AED treatment [<xref ref-type="bibr" rid="bibr74-2042098611433192">Palac and Meador, 2011</xref>].</p>
<p>As early as the 1960s, a relationship between the use of AEDs during pregnancy and MCMs was recognized [<xref ref-type="bibr" rid="bibr65-2042098611433192">Meadow, 1968</xref>]. For many years the risk of MCMs in children born to WWE treated with AEDs during pregnancy has been known to be approximately two to three times higher than the 1–2% frequency in the general population [<xref ref-type="bibr" rid="bibr74-2042098611433192">Palac and Meador, 2011</xref>]. More recent evidence suggests a special risk for valproate [<xref ref-type="bibr" rid="bibr64-2042098611433192">Meador <italic>et al</italic>. 2008b</xref>].</p>
<p>The risks of obstetrical complications in pregnant WWE are uncertain but could include increased risk of cesarean delivery, preeclampsia, pregnancy-induced hypertension, pregnancy bleeding complications, premature contractions or premature labor and delivery, and spontaneous abortion [<xref ref-type="bibr" rid="bibr27-2042098611433192">Harden <italic>et al</italic>. 2009a</xref>].</p>
<p>Perinatal/neonatal complications may include but are not limited to small for gestational age (SGA), low Apgar scores, and risk of perinatal death. Unfortunately, no studies have delineated many likely important contributing factors, including differences across AEDs, levels of <italic>in utero</italic> exposure, or epilepsy type.</p>
<p>Recently, the impact of fetal exposure to maternal AEDs on cognitive and behavioral development has emerged as an area of concern. Research efforts thus far suggest that maternal use of some AEDs during pregnancy may negatively impact cognition in the infants of WWE [<xref ref-type="bibr" rid="bibr74-2042098611433192">Palac and Meador, 2011</xref>). Evaluation and comparison of reports on AED teratogenicity, cognitive outcomes, and behavioral outcomes are difficult, even though considerable progress has been made recently in developing pregnancy registries. Outcome data are incomplete. Registries are observational investigations, have variable methodology, deal with different cultures and populations, have different definitions, have different standardized testing (e.g. different cognitive tests), and have variable follow-up times. These registries also have different data collection timing (e.g. MCMs at birth <italic>versus</italic> at 1 year old). Lack of information about mothers as well as lack of follow up restricts usefulness of registry data. In addition, each of the individual registries has weaknesses ranging from missing data on key variables to low numbers for specific AEDs [<xref ref-type="bibr" rid="bibr63-2042098611433192">Meador <italic>et al</italic>. 2008a</xref>, <xref ref-type="bibr" rid="bibr64-2042098611433192">2008b</xref>]. Given these limitations, signals for specific AEDs need to be reproduced in more than one registry to be confident of results.</p>
</sec>
<sec id="section2-2042098611433192">
<title>Seizure frequency during pregnancy</title>
<p>Because the appropriate gold standard comparator group (i.e. nonpregnant WWE) has not been employed, the American Academy of Neurology (AAN) concluded that there is insufficient evidence to determine if seizure frequency changes occur in WWE during pregnancy [<xref ref-type="bibr" rid="bibr27-2042098611433192">Harden <italic>et al</italic>. 2009a</xref>]. There has been wide variation in the reported range of women experiencing increased seizure frequency during pregnancy (9–75%). This variance may be due to differences in study populations and in other methodological issues. In addition, given the known pharmacokinetic changes during pregnancy, assessment of blood levels is needed in future studies [<xref ref-type="bibr" rid="bibr19-2042098611433192">EURAP, 2006</xref>; <xref ref-type="bibr" rid="bibr75-2042098611433192">Pennell and Hovinga, 2008</xref>; <xref ref-type="bibr" rid="bibr76-2042098611433192">Pennell <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr82-2042098611433192">Sabers, 2009</xref>; <xref ref-type="bibr" rid="bibr83-2042098611433192">Sabers and Petrenaite, 2009</xref>; <xref ref-type="bibr" rid="bibr79-2042098611433192">Petrenaite <italic>et al</italic>. 2009</xref>]. To provide more informed therapeutic strategies to maintain seizure control during pregnancy, clarification of factors that contribute to individual variance in increased seizures is important. Based on a number of studies from the literature, there is suggested increased seizure risk during pregnancy for lamotrigine and oxcarbazepine, both of which are glucuronidated for elimination [<xref ref-type="bibr" rid="bibr78-2042098611433192">Petrenaite <italic>et al</italic>. 2005</xref>, <xref ref-type="bibr" rid="bibr79-2042098611433192">2009</xref>; <xref ref-type="bibr" rid="bibr94-2042098611433192">Vajda <italic>et al</italic>. 2006b</xref>]. One positive finding concluded by the AAN found that WWE who were seizure free in the 9–12 months prior to pregnancy had an 85% chance of remaining so during pregnancy [<xref ref-type="bibr" rid="bibr27-2042098611433192">Harden <italic>et al</italic>. 2009a</xref>].</p>
<p>Although some WWE can safely discontinue AEDs prior to pregnancy, most require long-term AED therapy through pregnancy to control seizures. It is of paramount importance to control tonic–clonic seizures, which can result in fetal intracranial hemorrhage, transient fetal bradycardia or heartbeat variability, miscarriage or trauma and even death to the mother and the fetus [<xref ref-type="bibr" rid="bibr63-2042098611433192">Meador <italic>et al</italic>. 2008a</xref>]. Current treatment strategies in pregnant WWE employ AED monotherapy at the lowest dose to maintain stable blood levels and seizure control [<xref ref-type="bibr" rid="bibr63-2042098611433192">Meador <italic>et al</italic>. 2008a</xref>].</p>
</sec>
<sec id="section3-2042098611433192">
<title>Antiepileptic drug clearance in pregnancy</title>
<p>Data on AED clearance changes during pregnancy are lacking for many AEDs. For reasons largely unknown, considerable variability exists for AED clearance changes during pregnancy across AEDs and across individual patients [<xref ref-type="bibr" rid="bibr29-2042098611433192">Harden <italic>et al</italic>. 2009c</xref>; <xref ref-type="bibr" rid="bibr75-2042098611433192">Pennell <italic>et al</italic>. 2008a</xref>]. Of the AEDs studied, lamotrigine probably has the most marked clearance changes [<xref ref-type="bibr" rid="bibr75-2042098611433192">Pennell <italic>et al</italic>. 2008a</xref>]. Data are inadequate for most AEDs during pregnancy on the relationship between decreased AED concentrations, seizure frequency, as well as the role of AED level monitoring. Throughout pregnancy, lamotrigine total and free clearance increased with a peak of 94% (total) and 89% (free) in the third trimester, according to one class I study [<xref ref-type="bibr" rid="bibr29-2042098611433192">Harden <italic>et al</italic>. 2009c</xref>]. Importantly, when the lamotrigine level decreased to 65% of the preconceptional individualized target lamotrigine concentration, seizure frequency increased. Based on one class I and two class II studies [<xref ref-type="bibr" rid="bibr76-2042098611433192">Pennell <italic>et al</italic>. 2008b</xref>; <xref ref-type="bibr" rid="bibr91-2042098611433192">Tran <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr77-2042098611433192">Pennell <italic>et al</italic>. 2004</xref>], changes in the lamotrigine levels were associated with increases in seizure frequency. These data support active monitoring of AED levels during pregnancy, in particular, lamotrigine [<xref ref-type="bibr" rid="bibr29-2042098611433192">Harden <italic>et al</italic>. 2009c</xref>].</p>
<p>In addition to increased drug clearance, pregnancy causes dramatic changes in drug pharmacokinetics and leads to altered drug absorption, metabolism, and protein binding. Serial AED levels before pregnancy, during each trimester, and during the postpartum state may help guide appropriate dose augmentation or reduction [<xref ref-type="bibr" rid="bibr88-2042098611433192">St Louis, 2009</xref>]. Unfortunately, there is no consensus as to the frequency that drug levels should be drawn during pregnancy. However, a reasonable approach could be to draw AED levels monthly and then modify this schedule appropriately based on seizure frequency.</p>
</sec>
<sec id="section4-2042098611433192">
<title>Obstetrical risks</title>
<p>The AAN noted that ‘stronger evidence is needed to determine obstetrical risks for WWE, and the effect of specific AEDs on obstetrical outcomes also remains unexplored and deserves further study’ [<xref ref-type="bibr" rid="bibr27-2042098611433192">Harden <italic>et al</italic>. 2009a</xref>]. However, subsequent to that determination, two publications reported an increase in obstetrical complications in WWE, especially if on AEDs [<xref ref-type="bibr" rid="bibr49-2042098611433192">Kelly <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr101-2042098611433192">Veiby <italic>et al</italic>. 2009</xref>]. According to the AAN, cesarean section rates were probably not increased, but a moderately increased risk could not be ruled out secondary to statistical imprecision and contradictory findings. Two recent studies noted increased risk of cesarean section with odds ratio (OR) 1.5 [95% confidence interval (CI) 1.3–1.9] in one study [<xref ref-type="bibr" rid="bibr49-2042098611433192">Kelly <italic>et al</italic>. 2009</xref>] and OR 1.6 (95% CI 1.3—1.8) in the second study [<xref ref-type="bibr" rid="bibr101-2042098611433192">Veiby <italic>et al</italic>. 2009</xref>]. However, these publications did not address contributing factors. The AAN stated that in WWE who do not smoke there was likely no increased risk of preterm birth but a study challenged this finding [<xref ref-type="bibr" rid="bibr101-2042098611433192">Veiby <italic>et al</italic>. 2009</xref>]. Recently, a hospital-based, retrospective study [<xref ref-type="bibr" rid="bibr9-2042098611433192">Borthen <italic>et al</italic>. 2011</xref>] reported an increase in obstetrical complications in WWE on AEDs compared with a control group without epilepsy. The results showed that WWE on AEDs had an increased risk of severe preeclampsia (OR 5.0; 95% CI 1.3–19.9), bleeding in early pregnancy (OR 6.4; 95 CI 2.7–15.2), induction (OR 2.3; 95% CI 1.2–4.3) and cesarean section (OR 2.5; 95% CI 1.4–4.7) adjusted for maternal age, parity, education, smoking, medical conditions and body mass index &gt;30 kg/m<sup>2</sup> [<xref ref-type="bibr" rid="bibr9-2042098611433192">Borthen <italic>et al</italic>. 2011</xref>]. A number of these studies suffer from limitations, including retrospective data collection, use of national databases, and lack of specific information on AED use, dose, anticonvulsant blood levels, and epilepsy type.</p>
<p>Is there increased risk of pregnancy-induced hypertension in WWE? There was insufficient evidence to support or refute increased risk of pregnancy-induced hypertension based on results from two conflicting class II studies [<xref ref-type="bibr" rid="bibr27-2042098611433192">Harden <italic>et al</italic>. 2009a</xref>]. According to a class one study [<xref ref-type="bibr" rid="bibr102-2042098611433192">Viinikainen <italic>et al</italic>. 2006</xref>], WWE taking AEDs probably do not have a moderately increased risk of premature contractions and premature labor and delivery during pregnancy. However, according to one class II study [<xref ref-type="bibr" rid="bibr41-2042098611433192">Hvas <italic>et al</italic>. 2000</xref>], it is possible that WWE who smoke are at substantially increased risk of premature contractions and premature labor and delivery during pregnancy compared with smokers who do not have epilepsy. It is probable that WWE on AEDs do not have substantially increased risk of late pregnancy-related bleeding complications as per one class I and one class III study [<xref ref-type="bibr" rid="bibr27-2042098611433192">Harden <italic>et al</italic>. 2009a</xref>]. However, because of a lack of statistical precision in these studies, a moderately increased risk cannot be excluded. The data are inadequate to support or refute an increased risk of spontaneous abortion in WWE [<xref ref-type="bibr" rid="bibr27-2042098611433192">Harden <italic>et al</italic>. 2009a</xref>].</p>
</sec>
<sec id="section5-2042098611433192">
<title>Postpartum depression</title>
<p>Depression and psychological stress during and after pregnancy can have an adverse affect on outcomes in both the mother and child. This finding is supported by multiple publications [<xref ref-type="bibr" rid="bibr72-2042098611433192">O’Connor <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr99-2042098611433192">Van den Bergh <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr3-2042098611433192">Alder <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr38-2042098611433192">Horwitz <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr71-2042098611433192">Newport <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr13-2042098611433192">Deave <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr30-2042098611433192">Hay <italic>et al</italic>. 2008</xref>]. According to one study, there is an increased risk for depression in WWE [<xref ref-type="bibr" rid="bibr18-2042098611433192">Ettinger <italic>et al</italic>. 2004</xref>], and there is an even higher risk for postpartum depression suggested by three small studies [<xref ref-type="bibr" rid="bibr92-2042098611433192">Turner <italic>et al</italic>. 2006</xref>, <xref ref-type="bibr" rid="bibr93-2042098611433192">2009</xref>; <xref ref-type="bibr" rid="bibr24-2042098611433192">Galanti <italic>et al</italic>. 2009</xref>]. However, limited sample sizes and lack of comparator groups leave doubt in these three studies.</p>
</sec>
<sec id="section6-2042098611433192">
<title>Neonatal outcomes</title>
<p>With the exception of data on malformations, data in WWE on neonatal outcomes are insufficient. SGA is important due to increased risk of infant morbidity (e.g. neurodevelopment) and mortality [<xref ref-type="bibr" rid="bibr56-2042098611433192">Lundgren <italic>et al</italic>. 2008</xref>]. Based on two class II studies, the AAN concluded there is a probable increased risk for SGA [<xref ref-type="bibr" rid="bibr28-2042098611433192">Harden <italic>et al</italic>. 2009b</xref>]; and three recent studies also found increased SGA risk [<xref ref-type="bibr" rid="bibr49-2042098611433192">Kelly <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr101-2042098611433192">Veiby <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr11-2042098611433192">Chen <italic>et al</italic>. 2009</xref>]. See <xref ref-type="table" rid="table1-2042098611433192">Table 1</xref> for AAN classification of evidence of causality. Unfortunately, no studies have delineated many likely important contributing factors, including differences across AEDs, levels of <italic>in utero</italic> exposure, or epilepsy type. Based on two class II studies, the AAN concluded there is probably no increased risk of perinatal death, however a recent study did find an increased risk of fetal/infant death at 6 of 272 (2.2%) in WWE compared with 1 of 310 (0.3%) in controls (<italic>p</italic> = 0.05) [<xref ref-type="bibr" rid="bibr59-2042098611433192">Mawer <italic>et al</italic>. 2010</xref>]. There is possibly a lower 1 min Apgar score according to the AAN based on one class II study, and one recent study found lower 5 min Apgar scores in children of WWE [<xref ref-type="bibr" rid="bibr101-2042098611433192">Veiby <italic>et al</italic>. 2009</xref>]; however, many likely important contributing factors have not been assessed, including differential AED effects. Additionally, multiple pertinent outcomes with potential long-term implications on childhood health have not been addressed sufficiently [<xref ref-type="bibr" rid="bibr63-2042098611433192">Meador <italic>et al</italic>. 2008a</xref>; <xref ref-type="bibr" rid="bibr27-2042098611433192">Harden <italic>et al</italic>. 2009a</xref>, <xref ref-type="bibr" rid="bibr28-2042098611433192">2009b</xref>, <xref ref-type="bibr" rid="bibr29-2042098611433192">2009c</xref>].</p>
<table-wrap id="table1-2042098611433192" position="float">
<label>Table 1.</label>
<caption>
<p>American Academy of Neurology (AAN) criteria for classification of evidence for causality (adapted from Appendix e-4: Classification of evidence for causality, visit: <ext-link ext-link-type="uri" xlink:href="http://www.neurology.org/…/appendices_e-1_-_e-5_Tetatogenesis.doc">www.neurology.org/…/appendices_e-1_-_e-5_Tetatogenesis.doc</ext-link>).</p>
</caption>
<graphic alternate-form-of="table1-2042098611433192" xlink:href="10.1177_2042098611433192-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td><bold>Class I:</bold> Prospective cohort study design with representative sample and well defined risk factors and outcomes</td>
</tr>
<tr>
<td><bold>Class II:</bold> Retrospective cohort or case–control study designs</td>
</tr>
<tr>
<td><bold>Class III:</bold> Other cohort or case–control study designs with narrow spectrum or inadequate measures</td>
</tr>
<tr>
<td><bold>Class IV:</bold> Studies not meeting above criteria</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section7-2042098611433192">
<title>Mechanisms of anatomical teratogenesis</title>
<p>AEDs can produce both anatomical (i.e. MCM) or behavioral (i.e. cognitive) teratogenicity. Several theories have been posited for the mechanisms of teratogenesis in WWE on AEDs. Although the exact mechanisms are uncertain, current proposed mechanisms include folate deficiency, ischemia, neuronal suppression, reactive intermediates (e.g. free radicals or epoxides), and AED-induced neuronal apoptosis [<xref ref-type="bibr" rid="bibr62-2042098611433192">Meador <italic>et al</italic>. 2007</xref>]. It seems likely that the mechanisms underlying anatomical and behavioral teratogenesis are different because the highest risk of anatomical defects is from first-trimester AED exposure, but the highest risk of behavioral defects appears to be primarily from third-trimester exposure. The leading hypothesis for the mechanism leading to anatomical malformations involves free radical formation, while the leading hypothesis for the mechanism leading to behavioral/cognitive dysfunction involves AED-induced apoptosis and associated dysfunction in surviving neurons. Genetic predisposition likely plays a role and could involve interaction of teratogens with multiple-liability genes. This, in part, may explain the observed individual variability [<xref ref-type="bibr" rid="bibr21-2042098611433192">Finnell and Chernoff, 1987</xref>].</p>
</sec>
<sec id="section8-2042098611433192">
<title>Pregnancy outcomes with regard to congenital malformations</title>
<p>In recent years, several AED pregnancy registries have been established leading to new insights into teratogenic risks of AEDs. Pregnancy outcomes and other issues for WWE were examined for the new AAN guidelines, which included recommendations for patient care and future research [<xref ref-type="bibr" rid="bibr27-2042098611433192">Harden <italic>et al</italic>. 2009a</xref>, <xref ref-type="bibr" rid="bibr28-2042098611433192">2009b</xref>, <xref ref-type="bibr" rid="bibr29-2042098611433192">2009c</xref>].</p>
<p>There is an increased risk for MCMs in children of WWE <italic>versus</italic> the general population which has a frequency of 1.6–2.1% at birth [<xref ref-type="bibr" rid="bibr63-2042098611433192">Meador <italic>et al</italic>. 2008a</xref>]. There is variability in the risk estimates among studies, but a recent publication indicates 4.5% (OR 2.6) frequency for MCMs in AED monotherapy <italic>in utero</italic> exposure and 8.6% (OR 5.1) for AED polytherapy [<xref ref-type="bibr" rid="bibr63-2042098611433192">Meador <italic>et al</italic>. 2008a</xref>]. The most common MCMs associated with AEDs are heart malformations, orofacial defects, urologic defects, skeletal abnormalities, and neural tube defects. Specific examples include but are not limited to ventricular septal defect, cleft lip/cleft palate, hypospadias, radial ray defects, phalangeal hypoplasia, and spina bifida [<xref ref-type="bibr" rid="bibr63-2042098611433192">Meador <italic>et al</italic>. 2008a</xref>].</p>
</sec>
<sec id="section9-2042098611433192">
<title>Anatomical teratogenesis associated with individual antiepileptic drugs</title>
<p>Since the 1960s, AEDs have been known to have teratogenic potential. Since seizures carry the risk of potential injury or even death, most WWE cannot afford to discontinue AEDs. Therefore, it is important to delineate which AEDs produce the best seizure control while minimizing teratogenicity. AEDs taken during the first trimester of pregnancy may increase the risk of MCMs in children born to WWE. The AAN guidelines and a recent meta-analysis concluded that that risk is highest for valproate out of all the AEDs [<xref ref-type="bibr" rid="bibr28-2042098611433192">Harden <italic>et al</italic>. 2009b</xref>; <xref ref-type="bibr" rid="bibr64-2042098611433192">Meador <italic>et al</italic>. 2008b</xref>]. The recent European and International Registry of Antiepileptic Drugs in Pregnancy (EURAP) results confirmed the increased risk for valproate, but also demonstrated dose-dependent risks for other AEDs [<xref ref-type="bibr" rid="bibr90-2042098611433192">Tomson <italic>et al</italic>. 2011</xref>].</p>
<sec id="section10-2042098611433192">
<title>Carbamazepine</title>
<p>Carbamazepine has the most data in pregnancy compared with other AEDs. The AAN concluded that carbamazepine is probably not associated with a substantial increased risk of MCMs. One class I study showed no increased risk in children born to WWE taking carbamazepine [<xref ref-type="bibr" rid="bibr69-2042098611433192">Morrow <italic>et al</italic>. 2006</xref>]. The North American Pregnancy Registry reported in infants exposed <italic>in utero</italic> to carbamazepine a 2.6% overall risk of major malformations <italic>versus</italic> 1.62% in the general population; this difference was not statistically significant [<xref ref-type="bibr" rid="bibr34-2042098611433192">Holmes and Wyszynski, 2004</xref>]. There was increased risk for cleft lip/palate and neural tube defect noted by the same pregnancy registry [<xref ref-type="bibr" rid="bibr34-2042098611433192">Holmes and Wyszynski, 2004</xref>]. The recent large European Surveillance of Congenital Anomalies (EUROCAT) study confirmed the risk for spina bifida for carbamazepine monotherapy (OR 2.6, 95% CI 1.2—5.3 compared with no AED exposure). The risk for carbamazepine did not differ from other AED monotherapies but was less than valproic acid [<xref ref-type="bibr" rid="bibr45-2042098611433192">Jentink <italic>et al</italic>. 2010a</xref>]. However, the risk of cleft lip/palate was not confirmed in the EUROCAT study. This study had 19 population-based registries of congenital malformations in Europe based on over 3.8 million births. Another study with data taken from the EURAP epilepsy and pregnancy registry (an observational cohort study representing a collaboration of physicians from 42 countries) prospectively monitored pregnancies exposed to monotherapy with different doses of carbamazepine, lamotrigine, valproic acid, or phenobarbital with primary endpoint of MCMs detected up to 12 months after birth [<xref ref-type="bibr" rid="bibr90-2042098611433192">Tomson <italic>et al</italic>. 2011</xref>]. This study found a dose-dependent effect for carbamazepine and also found that risks of malformation were significantly higher with carbamazepine at doses greater than 400 mg per day compared with lamotrigine (see <xref ref-type="table" rid="table2-2042098611433192">Table 2</xref> for details).</p>
<table-wrap id="table2-2042098611433192" position="float">
<label>Table 2.</label>
<caption>
<p>Number of offspring with malformations for four monotherapies at different doses up to 1 year, taken from the European and International Registry of Antiepileptic Drugs in Pregnancy (EURAP), adapted from [<xref ref-type="bibr" rid="bibr90-2042098611433192">Tomson <italic>et al</italic>. 2011</xref>].</p>
</caption>
<graphic alternate-form-of="table2-2042098611433192" xlink:href="10.1177_2042098611433192-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Monotherapy (mg)</th>
<th align="left">Sample size</th>
<th align="left">Congenital malformation up to 1 year<xref ref-type="table-fn" rid="table-fn1-2042098611433192">*</xref></th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="3">Carbamazepine</td>
</tr>
<tr>
<td>&lt;400</td>
<td>148</td>
<td>5 (3.4%, 1.11–7.71</td>
</tr>
<tr>
<td>≥400 to &lt;1000</td>
<td>1047</td>
<td>56 (5.3%, 4.07–6.89)</td>
</tr>
<tr>
<td>≥1000</td>
<td>207</td>
<td>18 (8.7%, 5.24–13.39)</td>
</tr>
<tr>
<td colspan="3">Lamotrigine</td>
</tr>
<tr>
<td>&lt;300</td>
<td>836</td>
<td>17 (2.0%, 1.19–3.24)</td>
</tr>
<tr>
<td>≥300</td>
<td>444</td>
<td>20 (4.5%, 2.77–6.87)</td>
</tr>
<tr>
<td colspan="3">Phenobarbital</td>
</tr>
<tr>
<td>&lt;150</td>
<td>166</td>
<td>9 (5.4%, 2.51–10.04)</td>
</tr>
<tr>
<td>≥150</td>
<td>51</td>
<td>7 (13.7%, 5.70–26.26)</td>
</tr>
<tr>
<td colspan="3">Valproic acid</td>
</tr>
<tr>
<td>&lt;700</td>
<td>431</td>
<td>24 (5.6%, 3.60–8.17)</td>
</tr>
<tr>
<td>≥700 to &lt;1500</td>
<td>480</td>
<td>50 (10.4%, 7.83–13.50)</td>
</tr>
<tr>
<td>≥1500</td>
<td>99</td>
<td>24 (24.2%, 16.19–33.89)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-2042098611433192">
<label>*</label>
<p>Data are events (rate, 95% confidence interval).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section11-2042098611433192">
<title>Lamotrigine</title>
<p>Of the newer AEDs, lamotrigine has the most data for pregnancy outcomes with regard to risk of MCMs. A meta-analysis found a 2.91% risk of MCM [<xref ref-type="bibr" rid="bibr64-2042098611433192">Meador <italic>et al</italic>. 2008b</xref>]. One registry reported an increased risk of cleft lip/palate compared to a control group of over 200,000 unexposed infants from Brigham and Williams Hospital in Boston [<xref ref-type="bibr" rid="bibr35-2042098611433192">Holmes <italic>et al</italic>. 2006</xref>], but this was not confirmed in another study [<xref ref-type="bibr" rid="bibr14-2042098611433192">Dolk <italic>et al</italic>. 2008</xref>]. One class I study [<xref ref-type="bibr" rid="bibr69-2042098611433192">Morrow <italic>et al</italic>. 2006</xref>] observed no increased risk of MCMs in the offspring of WWE taking lamotrigine [relative risk (RR) 0.92, 95% CI 0.41–2.05] but was insufficiently sensitive to exclude a substantially increased risk. The AAN concluded that there is insufficient evidence to determine if lamotrigine increases the risk of MCMs in the offspring of WWE [<xref ref-type="bibr" rid="bibr28-2042098611433192">Harden <italic>et al</italic>. 2009b</xref>]. The AAN guidelines also concluded that lamotrigine probably has a lower rate of teratogenic outcomes compared with valproate [<xref ref-type="bibr" rid="bibr28-2042098611433192">Harden <italic>et al</italic>. 2009b</xref>]. Recent analysis of data from the EURAP epilepsy and pregnancy registry [<xref ref-type="bibr" rid="bibr90-2042098611433192">Tomson <italic>et al</italic>. 2011</xref>] assessed rates of MCMs in 1402 pregnancies exposed to carbamazepine, 1280 on lamotrigine, 1010 on valproic acid, and 217 on phenobarbital. An increase in malformation rates with increasing dose at the time of conception was recorded for all drugs [<xref ref-type="bibr" rid="bibr90-2042098611433192">Tomson <italic>et al</italic>. 2011</xref>]. This study found that compared with lamotrigine monotherapy at doses less than 300 mg per day [2.0% (17 events), 95% CI 1.19–3.24], risks of malformations (up to a year) were significantly higher with valproic acid and phenobarbital at all investigated doses, and with carbamazepine at doses greater than 400 mg per day [<xref ref-type="bibr" rid="bibr90-2042098611433192">Tomson <italic>et al</italic>. 2011</xref>] (see <xref ref-type="table" rid="table2-2042098611433192">Table 2</xref> for data on the four drugs, including doses, sample size, and ORs of congenital malformations)</p>
</sec>
<sec id="section12-2042098611433192">
<title>Levetiracetam</title>
<p>Preliminary findings on levetiracetam from the UK Registry revealed 3 of 117 exposed pregnancies had MCMs (2.7%; 95% CI 0.9–7.7%) [<xref ref-type="bibr" rid="bibr39-2042098611433192">Hunt <italic>et al</italic>. 2006</xref>]. The sample size is small so additional studies are needed to confirm these findings.</p>
</sec>
<sec id="section13-2042098611433192">
<title>Phenobarbital</title>
<p>Five (6.5%) of 77 pregnancies with exposure to phenobarbital monotherapy were associated with major malformations (95% CI 2.1–14.5%), which was significantly greater than the background rate (1.62%) (RR 4.2; 95% CI 1.5–9.4) [<xref ref-type="bibr" rid="bibr36-2042098611433192">Holmes <italic>et al</italic>. 2004</xref>]. In addition, a dose dependent effect on MCMs was found by the EURAP registry [<xref ref-type="bibr" rid="bibr90-2042098611433192">Tomson <italic>et al</italic>. 2011</xref>].</p>
</sec>
<sec id="section14-2042098611433192">
<title>Phenytoin</title>
<p>The Australian AED Pregnancy Registry reported a 10.5% risk of birth defects with fetal phenytoin exposure compared with 4.3% in those not exposed to AEDs [<xref ref-type="bibr" rid="bibr97-2042098611433192">Vajda <italic>et al</italic>. 2006a</xref>, <xref ref-type="bibr" rid="bibr96-2042098611433192">2007a</xref>, <xref ref-type="bibr" rid="bibr98-2042098611433192">2007b</xref>]. A meta-analysis found a 7.36% risk of MCMs for phenytoin monotherapy compared with 3.26% in those not exposed to AEDs, but this difference was not statistically significant due to large variance in the data [<xref ref-type="bibr" rid="bibr64-2042098611433192">Meador <italic>et al</italic>. 2008b</xref>]. The UK registry reported a 3.7% risk for phenytoin compared with 3.5% in those without AED exposure [<xref ref-type="bibr" rid="bibr69-2042098611433192">Morrow <italic>et al</italic>. 2006</xref>].</p>
</sec>
<sec id="section15-2042098611433192">
<title>Topiramate</title>
<p>The UK Registry examined pregnancies with topiramate monotherapy exposure and reported 3 of 70 had MCMs (4.8%; CI 1.7–13.3) [<xref ref-type="bibr" rid="bibr40-2042098611433192">Hunt <italic>et al</italic>. 2008</xref>]. These preliminary results await confirmation. The US Food and Drug Administration recently release a warning for increase of oral cleft (1.4% <italic>versus</italic> 0.38–0.55%) <italic>versus</italic> other AEDs (<ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm245777.htm">www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm245777.htm</ext-link>). This warning is based on unpublished data from the North American AED Pregnancy Registry and the UK AED Pregnancy Registry.</p>
</sec>
<sec id="section16-2042098611433192">
<title>Valproate</title>
<p>The AAN practice parameters concluded that valproate monotherapy possessed increased risk of MCMs compared to phenobarbitol, carbamazepine, phenytoin and lamotrigine [<xref ref-type="bibr" rid="bibr28-2042098611433192">Harden <italic>et al</italic>. 2009b</xref>]. The AAN recommended avoidance of valproate in the first trimester of pregnancy due to this risk [<xref ref-type="bibr" rid="bibr28-2042098611433192">Harden <italic>et al</italic>. 2009b</xref>]. This recommendation is supported by a recent meta-analysis, which found an overall risk of 10.73% for MCMs in children exposed <italic>in utero</italic> to valproate [<xref ref-type="bibr" rid="bibr64-2042098611433192">Meador <italic>et al</italic>. 2008b</xref>]. Valproate’s effect appears to be dose dependent, with doses greater than 1000 mg per day posing the greatest threat [<xref ref-type="bibr" rid="bibr4-2042098611433192">Artama <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr96-2042098611433192">Vajda <italic>et al</italic>. 2007a</xref>; <xref ref-type="bibr" rid="bibr90-2042098611433192">Tomson <italic>et al</italic>. 2011</xref>]. The recent large EUROCAT study found that use of valproate monotherapy was associated with significantly increased risks for six specific malformations; the odds ratios were, spina bifida 12.7-fold increased risk (95% CI 7.7–20.7); atrial septal defect 2.5 (95% CI 1.4–4.4); cleft palate 5.2 (95% CI 2.8–9.9); hypospadias 4.8 (95% CI 2.9–8.1); polydactyly 2.2 (95% CI 1.0–4.5); and craniosynostosis 6.8 (95% CI 1.8–18.8) [<xref ref-type="bibr" rid="bibr46-2042098611433192">Jentink <italic>et al</italic>. 2010b</xref>]. If possible, for WWE who are pregnant, avoidance of VPA should be considered to avoid the risk of MCMs.</p>
</sec>
<sec id="section17-2042098611433192">
<title>Benzodiazepines</title>
<p>Previous studies have concerned the possible teratogenic effect of benzodiazepines [<xref ref-type="bibr" rid="bibr15-2042098611433192">Dolovich <italic>et al</italic>. 1998</xref>; <xref ref-type="bibr" rid="bibr17-2042098611433192">Eros <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr53-2042098611433192">Laegreid <italic>et al</italic>. 1989</xref>, <xref ref-type="bibr" rid="bibr52-2042098611433192">1990</xref>; <xref ref-type="bibr" rid="bibr105-2042098611433192">Wikner <italic>et al</italic>. 2007</xref>]. The results of these studies are somewhat conflicting, but the largest studies with a minimum of bias indicate no marked teratogenicity [<xref ref-type="bibr" rid="bibr17-2042098611433192">Eros <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr105-2042098611433192">Wikner <italic>et al</italic>. 2007</xref>]. The main exceptions are the studies by Laegreid and colleagues which concern women who have used high amounts of such drugs.</p>
</sec>
<sec id="section18-2042098611433192">
<title>Other antiepileptic drugs</title>
<p>There are insufficient data to determine the risk for other AEDs. However, a recent population-based cohort study [<xref ref-type="bibr" rid="bibr67-2042098611433192">Molgaard-Nielsen and Hviid, 2011</xref>] of 837,795 live-born infants in Denmark from 1 January 1996 to 30 September 2008 may shed some light on this subject. Of the 1532 infants exposed to lamotrigine, oxcarbazepine, topiramate, gabapentin, or levetiracetam during the first trimester, 49 were diagnosed with a major birth defect compared with 19,911 of the 836,263 who were not exposed to an AED [3.2% <italic>versus</italic> 2.4%, respectively; adjusted prevalence odds ratio (POR) 0.99; 95% CI 0.72–1.36]. A major birth defect was diagnosed in 38 of 1019 infants (3.7%) exposed to lamotrigine during the first trimester (adjusted POR 1.18; 95% CI 0.83–1.68), in 11 of 393 infants (2.8%) exposed to oxcarbazepine (adjusted POR 0.86; 95% CI 0.46–1.59), and in 5 of 108 infants (4.6%) exposed to topiramate (adjusted POR 1.44; 95% CI 0.58–3.58). Gabapentin (<italic>n</italic> = 59) and levetiracetam (<italic>n</italic> = 58) exposure during the first trimester was uncommon, with only 1 (1.7%) and 0 infants diagnosed with birth defects, respectively. This study concluded that among live-born infants in Denmark, first-trimester exposure to lamotrigine, oxcarbazepine, topiramate, gabapentin, or levetiracetam compared with no exposure was not associated with an increased risk of major birth defects [<xref ref-type="bibr" rid="bibr67-2042098611433192">Molgaard-Nielsen and Hviid, 2011</xref>]. However, sample sizes were small except for lamotrigine and oxcarbazepine.</p>
</sec>
<sec id="section19-2042098611433192">
<title>Polytherapy</title>
<p>Polytherapy during the first trimester is probably associated with an increased risk of MCMs as per the AAN practice parameters [<xref ref-type="bibr" rid="bibr28-2042098611433192">Harden <italic>et al</italic>. 2009b</xref>]. The AAN advised that, if possible, AED polytherapy should be avoided in pregnancy to decrease the risk for MCMs [<xref ref-type="bibr" rid="bibr28-2042098611433192">Harden <italic>et al</italic>. 2009b</xref>]. According to a recent study, the risk of malformations was 3.1–7.8% in infants exposed to AED monotherapy, 8.3–13.5% in infants exposed to two AEDs, and more than 13.5% in infants exposed to three AEDs [<xref ref-type="bibr" rid="bibr47-2042098611433192">Kaaja <italic>et al</italic>. 2003</xref>]. Specific AED combinations carry uncertain risk for MCMs with the exception that polytherapy with valproate has a higher risk than polytherapy without valproate [<xref ref-type="bibr" rid="bibr27-2042098611433192">Harden <italic>et al</italic>. 2009a</xref>; <xref ref-type="bibr" rid="bibr69-2042098611433192">Morrow <italic>et al</italic>. 2006</xref>]. A recent study of a cohort of women from the North American AED Pregnancy Registry found that the risk of malformations among infants exposed to lamotrigine and carbamazepine as polytherapy during the first trimester was higher than the corresponding monotherapies only when the polytherapy included valproate [<xref ref-type="bibr" rid="bibr33-2042098611433192">Holmes <italic>et al</italic>. 2011</xref>].</p>
<p>One study [<xref ref-type="bibr" rid="bibr95-2042098611433192">Vajda <italic>et al</italic>. 2010</xref>] that utilized statistical analysis of malformation rate and AED exposure data from the Australian Register of Antiepileptic Drugs in Pregnancy showed the calculated RR value for AED polytherapy compared with monotherapy was below 1.0 in only three of 14 literature publications. In their register, the overall risks at 1 year postnatally for fetal malformations were 5.32% of 282 AED polytherapy pregnancies, and 7.84% of 791 AED monotherapy pregnancies, a RR of 0.68 (95% CI 0.39–1.17). For pregnancies exposed to valproate, the RR of fetal malformation (0.39, 95% CI 0.20–0.89) was lower in polytherapy (7.26%) than in monotherapy (17.9%); the difference did not depend on valproate dosage. The RR values for fetal malformation were not significantly different for AED polytherapy and monotherapy when valproate was not involved. Logistic regression suggested that coadministration of lamotrigine may have reduced the malformation risk from valproate [<xref ref-type="bibr" rid="bibr95-2042098611433192">Vajda <italic>et al</italic>. 2010</xref>]. The present results of this particular study suggest that it is therapy with valproate, rather than the number of AEDs taken during pregnancy, that is the primary factor associated with the presence of fetal malformations in the offspring [<xref ref-type="bibr" rid="bibr95-2042098611433192">Vajda <italic>et al</italic>. 2010</xref>].</p>
</sec>
<sec id="section20-2042098611433192">
<title>Conclusions for anatomical teratogenesis</title>
<p>Valproate poses special risk for MCMs (10.7%). Phenobarbital has possible increased risk (6.5%). Topiramate increases risk of oral cleft (1.4%). The risk of spina bifida is increased for valproate (12.7 times) and carbamazepine (2.6 times). Dose-dependent risks have been demonstrated for several AEDs, and could possibly exist across AEDs as a drug class. The absolute risks of most AEDs and specific polytherapy combinations are unknown.</p>
</sec>
</sec>
<sec id="section21-2042098611433192">
<title>Pregnancy outcomes with regard to neurodevelopment</title>
<sec id="section22-2042098611433192">
<title>Mechanisms of behavioral teratogenesis</title>
<p>Ethanol is known to produce widespread neuronal apoptosis leading to neurobehavioral deficits in the developing brain [<xref ref-type="bibr" rid="bibr42-2042098611433192">Ikonomidou <italic>et al</italic>. 2000</xref>]. There is also neuronal dysfunction found in the remaining neurons [<xref ref-type="bibr" rid="bibr66-2042098611433192">Medina <italic>et al</italic>. 2003</xref>]. These findings led to use of the apoptotic model in studies with AEDs. AEDs that have been observed to produce widespread neuronal apoptosis in neonatal rat brain include clonazepam, diazepam, phenobarbital, phenytoin, vigabatrin, and valproate [<xref ref-type="bibr" rid="bibr8-2042098611433192">Bittigau <italic>et al</italic>. 2002</xref>, <xref ref-type="bibr" rid="bibr7-2042098611433192">2003</xref>; <xref ref-type="bibr" rid="bibr5-2042098611433192">Asimiadou <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr87-2042098611433192">Stefovska <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr43-2042098611433192">Ikonomidou and Turski, 2010</xref>]. The effect is dose dependent, occurs at therapeutically relevant blood levels, and can occur with single dose exposure. It is also a synergistic effect since two AEDs, given at below threshold dosages, can still trigger the full apoptotic response. Many AEDs, which do not produce apoptosis in monotherapy, can enhance apoptosis induced by another AED [<xref ref-type="bibr" rid="bibr48-2042098611433192">Katz <italic>et al</italic>. 2007</xref>]. These include carbamazepine, lamotrigine, or topiramate [<xref ref-type="bibr" rid="bibr25-2042098611433192">Glier <italic>et al</italic>. 2004</xref>; <xref ref-type="bibr" rid="bibr58-2042098611433192">Manthey <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr50-2042098611433192">Kim <italic>et al</italic>. 2007</xref>]. This finding may suggest that polytherapy could increase the risk. The only AED of those tested thus far that does not produce apoptosis in monotherapy or enhance apoptosis of other AEDs is levetiracetam [<xref ref-type="bibr" rid="bibr58-2042098611433192">Manthey <italic>et al</italic>. 2005</xref>]. However, most AEDs have not been tested. Animal experiments like these naturally raise concern that some commonly utilized AEDs could produce similar adverse effects in children of WWE exposed <italic>in utero</italic>, but clinical studies are needed to confirm if similar effects occur in the human brain.</p>
<p>Another proposed mechanism that could potentially induce teratogenesis is AED alterations to neurotransmitter systems. This can affect both neuronal proliferation and migration. Multiple AEDs inhibit glutamate action, including felbamate and topiramate. Gamma-amino butyric acid (GABA) agonists include phenobarbital, benzodiazepines, and valproate. Neuronal differentiation and migration are largely regulated by the neurotransmitter medium in the developing brain. According to animal studies, blockade of N-methyl-<sc>d</sc>-aspartate (NMDA) receptors or enhanced GABA inhibition impairs neurogenesis and cell migration [<xref ref-type="bibr" rid="bibr57-2042098611433192">Manent <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr87-2042098611433192">Stefovska <italic>et al</italic>. 2008</xref>]. This can result in cortical dysplasias and decreased brain volume. Drug-induced inhibition of NMDA receptor activity [<xref ref-type="bibr" rid="bibr73-2042098611433192">Ogura <italic>et al</italic>. 2002</xref>] or enhanced GABA activity [<xref ref-type="bibr" rid="bibr106-2042098611433192">Wong and Wong, 2001</xref>] can disrupt the process of synaptogenesis. All these neurotransmitter changes and subsequent cellular changes in children exposed <italic>in utero</italic> to AEDs may account for impaired cognition [<xref ref-type="bibr" rid="bibr74-2042098611433192">Palac and Meador, 2011</xref>].</p>
</sec>
</sec>
<sec id="section23-2042098611433192">
<title>Cognitive effects of maternal epilepsy in absence of antiepileptic drugs during pregnancy</title>
<p>Based on a prospective, blinded, and observational study [<xref ref-type="bibr" rid="bibr23-2042098611433192">Gaily <italic>et al</italic>. 2004</xref>] and a blinded retrospective study [<xref ref-type="bibr" rid="bibr37-2042098611433192">Holmes <italic>et al</italic>. 2000</xref>], no IQ difference was found between children of untreated WWE and healthy controls.</p>
</sec>
<sec id="section24-2042098611433192">
<title>Cognitive effects of maternal seizures during pregnancy</title>
<p>In children exposed <italic>in utero</italic> to self-limiting (i.e. no status epilepticus) generalized tonic–clonic seizures, two prospective population-based studies found no IQ impairment [<xref ref-type="bibr" rid="bibr22-2042098611433192">Gaily <italic>et al</italic>. 1988</xref>, <xref ref-type="bibr" rid="bibr23-2042098611433192">2004</xref>). However, verbal IQ was significantly reduced in children exposed to more than four generalized tonic–clonic seizures based on a retrospective study [<xref ref-type="bibr" rid="bibr2-2042098611433192">Adab <italic>et al</italic>. 2004</xref>]. It has been documented in case reports that prolonged seizures and status epilepticus are a serious threat to both mother and fetus [<xref ref-type="bibr" rid="bibr32-2042098611433192">Hiilesman, 1996</xref>].</p>
</sec>
<sec id="section25-2042098611433192">
<title>Effects of fetal antiepileptic drug exposure on neurodevelopment</title>
<p>Animal studies have shown that fetal exposure to AEDs at doses lower than the threshold required to produce congenital malformations is known to produce cognitive and behavioral abnormalities [<xref ref-type="bibr" rid="bibr60-2042098611433192">Meador <italic>et al</italic>. 2011</xref>].</p>
</sec>
<sec id="section26-2042098611433192">
<title>Neurodevelopmental effects of individual antiepileptic drugs</title>
<sec id="section27-2042098611433192">
<title>Carbamazepine</title>
<p>In a prospective, evaluator-blinded, observational study with matched controls, no effect of fetal carbamazepine exposure on IQ was reported [<xref ref-type="bibr" rid="bibr84-2042098611433192">Scolnik <italic>et al</italic>. 1994</xref>]. In a population-based, longitudinal follow-up study of preschool children, no adverse effects of fetal carbamazepine exposure were seen [<xref ref-type="bibr" rid="bibr104-2042098611433192">Wide <italic>et al</italic>. 2002</xref>]. A retrospective, blinded study controlling for maternal IQ in 52 children of WWE exposed to carbamazepine <italic>versus</italic> 80 unexposed children found no IQ difference [<xref ref-type="bibr" rid="bibr2-2042098611433192">Adab <italic>et al</italic>. 2004</xref>]. In a prospective, population-based, blinded, observational study controlling for maternal education, no difference in IQ was seen in 86 children of WWE exposed to carbamazepine monotherapy <italic>versus</italic> 45 children of WWE on no AED or 141 healthy control children [<xref ref-type="bibr" rid="bibr23-2042098611433192">Gaily <italic>et al</italic>. 2004</xref>]. When these data were pooled with data from another prospective population-based study, mental retardation occurred in only 1 of 84 children exposed to polytherapy [<xref ref-type="bibr" rid="bibr22-2042098611433192">Gaily <italic>et al</italic>. 1988</xref>, <xref ref-type="bibr" rid="bibr23-2042098611433192">2004</xref>]. In a population-based, evaluator-blinded study, again no IQ difference was seen in children of WWE exposed to carbamazepine <italic>versus</italic> no AED [<xref ref-type="bibr" rid="bibr16-2042098611433192">Eriksson <italic>et al</italic>. 2005</xref>]. A retrospective population-based study on autism spectrum disorder in 80 children exposed to carbamazepine monotherapy showed no difference in frequency from the general population [<xref ref-type="bibr" rid="bibr80-2042098611433192">Rasalam <italic>et al</italic>. 2005</xref>]. At age 3 years, children exposed <italic>in utero</italic> to carbamazepine did not differ from lamotrigine or phenytoin, but had better IQ outcomes than valproate in a prospective observational multicenter study [<xref ref-type="bibr" rid="bibr61-2042098611433192">Meador <italic>et al</italic>. 2009</xref>]. Based on the same study, a follow-up investigation showed fetal exposure to carbamazepine was associated with a dose-related reduction in language abilities at age 3 years, but this finding requires replication [<xref ref-type="bibr" rid="bibr60-2042098611433192">Meador <italic>et al</italic>. 2011</xref>].</p>
</sec>
<sec id="section28-2042098611433192">
<title>Lamotrigine</title>
<p>Children at age 3 years exposed <italic>in utero</italic> to lamotrigine did not differ from those exposed to carbamazepine or phenytoin, but had better IQ outcomes than those exposed to valproate at age 3 in a prospective observational multicenter study [<xref ref-type="bibr" rid="bibr61-2042098611433192">Meador <italic>et al</italic>. 2009</xref>]. In a follow-up investigation, dose-related effects of fetal AED exposure on verbal and nonverbal cognitive measures were assessed in exposed 3-year-old children [<xref ref-type="bibr" rid="bibr60-2042098611433192">Meador <italic>et al</italic>. 2011</xref>]. This study sought to determine if differential long-term neurodevelopmental effects exist across four commonly used AEDs (carbamazepine, lamotrigine, phenytoin, and valproate). Cognitive outcomes were calculated in 216 children from the Differential Ability Scales, Preschool Language Scale, Peabody Picture Vocabulary Test and Developmental Test of Visual-Motor Integration. Verbal abilities were lower than nonverbal in children exposed <italic>in utero</italic> to each drug. No dose effects were seen for lamotrigine and phenytoin [<xref ref-type="bibr" rid="bibr60-2042098611433192">Meador <italic>et al</italic>. 2011</xref>].</p>
</sec>
<sec id="section29-2042098611433192">
<title>Levetiracetam</title>
<p>A recent study comparing levetiracetam to valproate and to a control group reported that children exposed to levetiracetam obtained higher developmental scores at less than age 24 months compared with children exposed to valproate (<italic>n</italic> = 51 levetiracetam; <italic>n</italic> = 44 valproate; <italic>p</italic> &lt; 0.001). The levetiracetam group did not differ from control children (<italic>n</italic> = 97; <italic>p</italic> = 0.62) [<xref ref-type="bibr" rid="bibr85-2042098611433192">Shallcross <italic>et al</italic>. 2011</xref>]. Limitations of the study included young age at assessment, retrospective approach, and completer rates of only 58% for levetiracetam and 37% for valproate. So, replication of the findings is needed. Given these limitations and that this is the only study on neurodevelopment effects of levetiracetam, caution should be exercised when utilizing this source for clinical application.</p>
</sec>
<sec id="section30-2042098611433192">
<title>Phenobarbital</title>
<p>According to a study done in 1976, no difference in IQ was seen in 35 children of WWE exposed <italic>in utero</italic> to phenobarbital monotherapy <italic>versus</italic> 4705 children of mothers without epilepsy [<xref ref-type="bibr" rid="bibr86-2042098611433192">Shapiro <italic>et al</italic>. 1976</xref>]. In contrast, two studies of separate cohorts of 114 adult men of mothers without epilepsy, exposed <italic>in utero</italic> to phenobarbital, found approximately 0.5 standard deviation lower verbal IQ scores in the exposed men [<xref ref-type="bibr" rid="bibr81-2042098611433192">Reinisch <italic>et al</italic>. 1995</xref>]. Young children exposed to phenobarbital have also been shown to have statistically different IQ scores than control groups. While not a study of fetal exposure, one investigation of phenobarbital in young children with febrile seizures offers insights into the effects of phenobarbital on the immature brain. A total of 217 children with febrile seizures were randomized to a phenobarbital or placebo, and tested 2 years later; those exposed to phenobarbital had lower IQ [<xref ref-type="bibr" rid="bibr20-2042098611433192">Farwell <italic>et al</italic>. 1990</xref>]. Avoidance of phenobarbital in WWE during pregnancy, if possible, may be considered to reduce the risk of poor cognitive outcomes (level C) [<xref ref-type="bibr" rid="bibr28-2042098611433192">Harden <italic>et al</italic>. 2009b</xref>].</p>
</sec>
<sec id="section31-2042098611433192">
<title>Phenytoin</title>
<p>In two prospective, blinded, population-based studies that controlled for socioeconomic class or maternal educational level, no effect of fetal phenytoin exposure on IQ was seen [<xref ref-type="bibr" rid="bibr86-2042098611433192">Shapiro <italic>et al</italic>. 1976</xref>; <xref ref-type="bibr" rid="bibr22-2042098611433192">Gaily <italic>et al</italic>. 1988</xref>]. Another study drawn from a different patient pool but of the same design noted lower IQ at age 7 years in children of WWE exposed to phenytoin <italic>versus</italic> healthy control children of mothers without epilepsy [<xref ref-type="bibr" rid="bibr26-2042098611433192">Hanson <italic>et al</italic>. 1976</xref>]. In a population-based longitudinal follow-up study of preschool children, slightly lower scores for locomotor development were reported in phenytoin-exposed children <italic>versus</italic> fetal carbamazepine-exposed children and unexposed children [<xref ref-type="bibr" rid="bibr104-2042098611433192">Wide <italic>et al</italic>. 2002</xref>]. In a case– control, blinded-evaluator study, phenytoin-exposed children had significantly lower IQ scores [<xref ref-type="bibr" rid="bibr100-2042098611433192">Vanoverloop <italic>et al</italic>. 1992</xref>]. Although a prospective, blinded observational study reported lower IQ for children with fetal phenytoin exposure compared with matched control [<xref ref-type="bibr" rid="bibr84-2042098611433192">Scolnik <italic>et al</italic>. 1994</xref>], no effect was seen when maternal IQ was considered [<xref ref-type="bibr" rid="bibr54-2042098611433192">Loring <italic>et al</italic>. 1994</xref>]. Children at age 3 who were exposed to phenytoin <italic>in utero</italic> had better IQ outcomes than those exposed to valproate but did not differ from those exposed to carbamazepine or lamotrigine in a prospective observational multicenter study of monotherapy [<xref ref-type="bibr" rid="bibr61-2042098611433192">Meador <italic>et al</italic>. 2009</xref>]. The AAN recommended avoiding phenytoin in WWE during pregnancy based on level C evidence [<xref ref-type="bibr" rid="bibr28-2042098611433192">Harden <italic>et al</italic>. 2009b</xref>], but firm conclusions on the risks of phenytoin will require additional studies.</p>
</sec>
<sec id="section32-2042098611433192">
<title>Valproate</title>
<p>Two prospective, population-based, evaluator-blinded studies demonstrated lower verbal IQ or full-scale IQ in children of WWE exposed <italic>in utero</italic> to valproate monotherapy compared with children with carbamazepine monotherapy or no AED exposure [<xref ref-type="bibr" rid="bibr23-2042098611433192">Gaily <italic>et al</italic>. 2004</xref>; <xref ref-type="bibr" rid="bibr16-2042098611433192">Eriksson <italic>et al</italic>. 2005</xref>]. Unfortunately, the size of the sample valproate monotherapy group limited these studies (<italic>n</italic> = 26 across the two studies). In addition, the studies showed significantly lower maternal education or IQ in the valproate group compared with other WWE. In a retrospective study, there was an increased need for special education in children exposed to valproate monotherapy compared with other monotherapies or the unexposed group [<xref ref-type="bibr" rid="bibr1-2042098611433192">Adab <italic>et al</italic>. 2001</xref>]. In a large retrospective investigation that controlled for maternal IQ, lower verbal IQ (about 10 points) was seen in children exposed <italic>in utero</italic> to valproate (<italic>n</italic> = 41) <italic>versus</italic> other monotherapy groups and <italic>versus</italic> an unexposed group [<xref ref-type="bibr" rid="bibr2-2042098611433192">Adab <italic>et al</italic>. 2004</xref>]. The decrease in IQ in the valproate group was a dose-dependent effect. Another study showed children exposed <italic>in utero</italic> to valproate had lower IQ (7–9 points) at age 3 years compared with other AEDs (carbamazepine, lamotrigine, or phenytoin); this was a prospective, observational, evaluator-blinded, multicenter study, which enrolled pregnant WWE on AED monotherapy [<xref ref-type="bibr" rid="bibr61-2042098611433192">Meador <italic>et al</italic>. 2009</xref>]. The adverse effect of valproate was dose dependent [<xref ref-type="bibr" rid="bibr61-2042098611433192">Meador <italic>et al</italic>. 2009</xref>]. According to a follow-up analysis in the same study, verbal and nonverbal cognitive outcomes were reduced in children exposed <italic>in utero</italic> to valproate monotherapy <italic>versus</italic> carbamazepine, lamotrigine, and phenytoin. Again, the effect was dose dependent, and the impact of the effect appeared greater in verbal than in nonverbal abilities [<xref ref-type="bibr" rid="bibr60-2042098611433192">Meador <italic>et al</italic>. 2011</xref>]. Two retrospective and one prospective study have posited an increased risk for autistic spectrum disorder or behavioral abnormalities in valproate-exposed children [<xref ref-type="bibr" rid="bibr80-2042098611433192">Rasalam <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr10-2042098611433192">Bromley <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr103-2042098611433192">Vinten <italic>et al</italic>. 2009</xref>]. In a recent study [<xref ref-type="bibr" rid="bibr70-2042098611433192">Nadebaum <italic>et al</italic>. 2011</xref>], IQ was evaluated in school-aged children exposed to valproate and polytherapy during pregnancy (using the Wechsler Intelligence Scale for Children – fourth edition). The study results suggested that valproate has a dose-dependent negative impact on verbal intellectual abilities, and may also affect working memory. In addition, the possibility that inclusion of valproate in polytherapy regimens may underlie reduced mean scores was discussed [<xref ref-type="bibr" rid="bibr70-2042098611433192">Nadebaum <italic>et al</italic>. 2011</xref>]. Avoiding valproate in WWE during pregnancy, if possible, should be considered to reduce the risk of poor cognitive and verbal outcomes (level B) [<xref ref-type="bibr" rid="bibr28-2042098611433192">Harden <italic>et al</italic>. 2009b</xref>].</p>
</sec>
<sec id="section33-2042098611433192">
<title>Benzodiazepines</title>
<p>The risks of fetal exposure to cognition and behavior due to benzodiazepines are largely unknown secondary to a lack of adequate data in human studies.</p>
</sec>
<sec id="section34-2042098611433192">
<title>Other antiepileptic drugs</title>
<p>The risks of fetal exposure to cognition and behavior due to other AEDs are largely unknown secondary to a lack of adequate data in human studies.</p>
</sec>
<sec id="section35-2042098611433192">
<title>Polytherapy</title>
<p>No difference in IQ was found among children exposed to phenytoin and phenobarbital polytherapy <italic>versus</italic> other children of WWE according to one prospective study done in the 1970s [<xref ref-type="bibr" rid="bibr86-2042098611433192">Shapiro <italic>et al</italic>. 1976</xref>]. Subsequent prospective studies have found otherwise. Children exposed <italic>in utero</italic> to AED polytherapy had lower cognitive scores than healthy controls and children of WWE exposed to monotherapy [<xref ref-type="bibr" rid="bibr55-2042098611433192">Lösche <italic>et al</italic>. 1994</xref>]. Children exposed <italic>in utero</italic> to AED polytherapy had impaired verbal and nonverbal IQ compared with children exposed to monotherapy alone [<xref ref-type="bibr" rid="bibr51-2042098611433192">Koch <italic>et al</italic>. 1999</xref>; <xref ref-type="bibr" rid="bibr23-2042098611433192">Gaily <italic>et al</italic>. 2004</xref>]. If possible, AED polytherapy should be avoided in WWE to reduce the risk of poor cognitive and verbal outcomes.</p>
</sec>
<sec id="section36-2042098611433192">
<title>Conclusions on cognitive outcomes from human studies</title>
<p>From the current literature, the most salient point regarding a specific AED is that fetal valproate exposure poses a special risk for cognitive development in the child, and that this effect is dose dependent. As mentioned earlier, valproate also carries the risk of anatomical teratogenesis in addition to the behavioral/cognitive risks. Carbamazepine and lamotrigine appear to have low risk based on current studies. Due to inconsistent or absent data, the risks for other AEDs are uncertain. It appears that polytherapy exposure poses a risk to cognitive development based on limited studies; however, the risks of specific AED combinations are unclear. A myriad of questions remain unresolved, and there is a critical need for more research.</p>
</sec>
</sec>
<sec id="section37-2042098611433192">
<title>Folate effects</title>
<p>According to one study, folate deficiency during pregnancy reduces neurogenesis and increases apoptosis [<xref ref-type="bibr" rid="bibr12-2042098611433192">Craciunescu <italic>et al</italic>. 2004</xref>], but folate nutritional status during pregnancy has not been proven to impact neurodevelopment [<xref ref-type="bibr" rid="bibr89-2042098611433192">Tamura <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr62-2042098611433192">Meador <italic>et al</italic>. 2007</xref>]. Does preconceptional folic acid supplementation in WWE reduce the risk for MCMs in the fetus? In the current literature, there are insufficient data to answer this question. The risk for MCMs in offspring of WWE is possibly decreased by folic acid supplementation based on two adequately sensitive class III studies [<xref ref-type="bibr" rid="bibr6-2042098611433192">Betts and Fox, 1999</xref>; <xref ref-type="bibr" rid="bibr47-2042098611433192">Kaaja <italic>et al</italic>. 2003</xref>]. The current recommendation in WWE is that preconceptional folic acid supplementation may be considered to reduce the risk of MCMs (level C) [<xref ref-type="bibr" rid="bibr29-2042098611433192">Harden <italic>et al</italic>. 2009c</xref>]. In one study [<xref ref-type="bibr" rid="bibr107-2042098611433192">Wyszynski <italic>et al</italic>. 2005</xref>] of a sample from the North American Antiepileptic Drug Pregnancy Registry, 149 valproate-exposed women (all of whom were on folic acid supplementation) during the first trimester of pregnancy had 16 children with neural tube defects identified (proportion 10.7%; 95% CI 6.3–16.9%). The prevalence in the internal comparison group was 2.9% (95% CI 2.0–4.1%; OR 4.0, 95% CI 2.1–7.4; <italic>p</italic> &lt; 0.001). Assuming a 1.62% prevalence in the external comparison group, the RR of having an affected offspring for valproate-exposed women was 7.3 (95% CI 4.4–12.2; <italic>p</italic> &lt; 0.001). The mothers of all 16 infants took either prenatal vitamins/multivitamins or supplemental folic acid in the periconceptional period with a dose average of 1.36 mg and a range of 0.4–5 mg. These findings demonstrate the occurrence of neural tube defects in spite of periconceptional supplementation with folic acid. This finding in this case series should not be considered a definitive assessment of whether or not periconceptional supplementation with folic acid reduces the occurrence of neural tube defects when the mother is taking valproate as monotherapy [<xref ref-type="bibr" rid="bibr107-2042098611433192">Wyszynski <italic>et al</italic>. 2005</xref>].</p>
<p>In one prospective, observational, registration and follow-up study [<xref ref-type="bibr" rid="bibr68-2042098611433192">Morrow <italic>et al</italic>. 2009</xref>], 1935 cases reported to have received preconceptual folic acid (patients were included whether or not they were on AEDs), 76 MCMs (3.9%; 95% CI 3.1–4.9) and eight neural tube defects (0.4%; 95% CI 0.2–0.8) were identified. For 2375 women who were reported to have received folic acid but not until later in the pregnancy (<italic>n</italic> = 1825) or not at all (<italic>n</italic> = 550), there were 53 outcomes with an MCM (2.2%; 95% CI 1.7–2.9) and eight neural tube defects (0.34%; 95% CI 0.2–0.7). This study [<xref ref-type="bibr" rid="bibr68-2042098611433192">Morrow <italic>et al</italic>. 2009</xref>] supports the view that the increased risk of MCMs recorded in this group may occur through mechanisms other than that of folic acid metabolism.</p>
<p>In a case–control study [<xref ref-type="bibr" rid="bibr44-2042098611433192">Jentink <italic>et al</italic>. 2009</xref>] with data from a population-based registry (EUROCAT Northern Netherlands) of congenital malformations the risk for spina bifida was decreased with folate use in AED unexposed pregnancies (OR 0.5; 95% CI 0.3–0.7), but not among valproate-exposed pregnancies (OR 1.0; 95% CI 0.1–7.6). Further research is needed to establish the most effective form and dose of folic acid in women who use valproate [<xref ref-type="bibr" rid="bibr44-2042098611433192">Jentink <italic>et al</italic>. 2009</xref>].</p>
<p>The result concerning folate supplementation from the EURAP study [<xref ref-type="bibr" rid="bibr90-2042098611433192">Tomson <italic>et al</italic>. 2011</xref>] showed folate supplementation was associated with a greater risk of MCMs. However, this possibly shows confounding by indication because women at greater risk are more likely to take folate. The UK registry (<xref ref-type="bibr" rid="bibr68-2042098611433192">Morrow <italic>et al</italic>. 2009</xref>] reported rates of MCMs in offspring of women on AEDs with appropriate folate intake that were at least as high as those in women on AEDs without appropriate folate intake.</p>
<p>Though the data are insufficient to show that folic acid supplementation is effective in WWE, it is generally recommended to reduce risk of MCMs during pregnancy. There is no evidence of harm. Therefore, the current recommendation is that women with or without epilepsy be supplemented with at least 0.4 mg folic acid daily prior to and during pregnancy. The current literature is insufficient to address the dosing of folic acid and does not address if there is a dose effect protective benefit to WWE taking AEDs [<xref ref-type="bibr" rid="bibr29-2042098611433192">Harden <italic>et al</italic>. 2009c</xref>].</p>
</sec>
<sec id="section38-2042098611433192">
<title>Vitamin K</title>
<p>In neonates born to WWE taking AEDs, what is the risk of hemorrhagic disease? The evidence is not sufficient to determine if the risk of neonatal hemorrhagic complications in the newborns of WWE taking AEDs is substantially increased (one inadequately sensitive class II study) [<xref ref-type="bibr" rid="bibr29-2042098611433192">Harden <italic>et al</italic>. 2009c</xref>]. Does prenatal vitamin K supplementation reduce the risk of hemorrhagic complications in the newborns of WWE taking AEDs? The evidence is insufficient to determine the answer. In newborns of WWE, there is inadequate evidence to support or refute a benefit of prenatal vitamin K supplementation for risk reduction of hemorrhagic complications. Newborns exposed to enzyme-inducing AEDs <italic>in utero</italic> should routinely receive vitamin K at delivery, as is the routine practice for all newborns [<xref ref-type="bibr" rid="bibr29-2042098611433192">Harden <italic>et al</italic>. 2009c</xref>].</p>
</sec>
<sec id="section39-2042098611433192" sec-type="conclusions">
<title>Conclusions</title>
<p>Though discontinuing AEDs prior to pregnancy may be an option in some WWE with mild seizures, most are unable to safely stop AEDs. Therefore, of necessity, their fetus must be exposed. Present guidelines are constructed to minimize risk to the fetus and the mother while obtaining maximal benefit of seizure control. This includes optimizing epilepsy treatment prior to conception, choosing the most effective AED to control seizures, using monotherapy and lowest effective dose if possible, and supplementing with folate. The guidelines also recommend avoiding valproate when possible. Sudden cessation or lowering of AEDs should not be done by a WWE without consultation with her physician [<xref ref-type="bibr" rid="bibr63-2042098611433192">Meador <italic>et al</italic>. 2008a</xref>]. Once it is determined that a WWE is to continue on AEDs during pregnancy, she must be informed of the relative risks and guided appropriately in her therapy. Delineation of these risks should be placed in the context that most children born to WWE are normal.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>The authors have received no sources of financial or material support for this article.</p>
</fn>
<fn fn-type="conflict">
<p>The authors declare no conflicts of interest in preparing this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Adab</surname><given-names>N.</given-names></name>
<name><surname>Jacoby</surname><given-names>A.</given-names></name>
<name><surname>Smith</surname><given-names>D.</given-names></name>
<name><surname>Chadwick</surname><given-names>D.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Additional educational needs in children born to mothers with epilepsy</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <volume>70</volume>: <fpage>15</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr2-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Adab</surname><given-names>N.</given-names></name>
<name><surname>Kini</surname><given-names>U.</given-names></name>
<name><surname>Vinten</surname><given-names>J.</given-names></name>
<name><surname>Ayres</surname><given-names>J.</given-names></name>
<name><surname>Baker</surname><given-names>G.</given-names></name>
<name><surname>Clayton-Smith</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>The longer term outcome of children born to mothers with epilepsy</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <volume>75</volume>: <fpage>1575</fpage>–<lpage>1583</lpage>.</citation>
</ref>
<ref id="bibr3-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alder</surname><given-names>J.</given-names></name>
<name><surname>Fink</surname><given-names>N.</given-names></name>
<name><surname>Bitzer</surname><given-names>J.</given-names></name>
<name><surname>Hösli</surname><given-names>I.</given-names></name>
<name><surname>Holzgreve</surname><given-names>W.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Depression and anxiety during pregnancy: a risk factor for obstetric, fetal and neonatal outcome? A critical review of the literature</article-title>. <source>J Matern Fetal Neonatal Med</source> <volume>20</volume>: <fpage>189</fpage>–<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr4-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Artama</surname><given-names>M.</given-names></name>
<name><surname>Auvinen</surname><given-names>A.</given-names></name>
<name><surname>Raudaskoski</surname><given-names>T.</given-names></name>
<name><surname>Isojärvi</surname><given-names>I.</given-names></name>
<name><surname>Isojärvi</surname><given-names>J.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Antiepileptic drug use of women with epilepsy and congenital malformations in offspring</article-title>. <source>Neurology</source> <volume>64</volume>: <fpage>1874</fpage>–<lpage>1878</lpage>.</citation>
</ref>
<ref id="bibr5-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Asimiadou</surname><given-names>S.</given-names></name>
<name><surname>Bittigau</surname><given-names>P.</given-names></name>
<name><surname>Felderhoff-Mueser</surname><given-names>U</given-names></name>
<name><surname>Manthey</surname><given-names>D.</given-names></name>
<name><surname>Sifringer</surname><given-names>M.</given-names></name>
<name><surname>Pesditschek</surname><given-names>S.</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Protection with estradiol in developmental models of apoptotic neurodegeneration</article-title>. <source>Ann Neurol</source> <volume>58</volume>: <fpage>266</fpage>–<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr6-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Betts</surname><given-names>T.</given-names></name>
<name><surname>Fox</surname><given-names>C.</given-names></name>
</person-group> (<year>1999</year>). <article-title>Proactive preconception counseling for women with epilepsy: is it effective?</article-title> <source>Seizure</source> <volume>8</volume>: <fpage>322</fpage>–<lpage>327</lpage>.</citation>
</ref>
<ref id="bibr7-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bittigau</surname><given-names>P.</given-names></name>
<name><surname>Sifringer</surname><given-names>M.</given-names></name>
<name><surname>Ikonomidou</surname><given-names>C.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Antiepileptic drugs and apoptosis in the developing brain</article-title>. <source>Ann N Y Acad Sci</source> <volume>993</volume>:<fpage>103</fpage>-<lpage>14</lpage>; <comment>discussion 123–4</comment>.</citation>
</ref>
<ref id="bibr8-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bittigau</surname><given-names>P.</given-names></name>
<name><surname>Sifringer</surname><given-names>M.</given-names></name>
<name><surname>Genz</surname><given-names>K.</given-names></name>
<name><surname>Manthey</surname><given-names>D.</given-names></name>
<name><surname>Sifringer</surname><given-names>M.</given-names></name>
<name><surname>Pesditschek</surname><given-names>S.</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>Antiepileptic drugs and apoptotic neurodegeneration in the developing brain</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>99</volume>: <fpage>15089</fpage>–<lpage>15094</lpage>.</citation>
</ref>
<ref id="bibr9-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Borthen</surname><given-names>I.</given-names></name>
<name><surname>Eide</surname><given-names>M.</given-names></name>
<name><surname>Daltveit</surname><given-names>A.</given-names></name>
<name><surname>Gihus</surname><given-names>N.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Obstetric outcome in women with epilepsy: a hospital-based, retrospective study</article-title>. <source>BJOG</source> <volume>118</volume>: <fpage>956</fpage>–<lpage>965</lpage>.</citation>
</ref>
<ref id="bibr10-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bromley</surname><given-names>R.L.</given-names></name>
<name><surname>Mawer</surname><given-names>G.</given-names></name>
<name><surname>Clayton-Smith</surname><given-names>J.</given-names></name>
<name><surname>Baker</surname><given-names>G.A.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Autism spectrum disorders following in utero exposure to antiepileptic drugs</article-title>. <source>Neurology</source> <volume>71</volume>: <fpage>1923</fpage>–<lpage>1924</lpage>.</citation>
</ref>
<ref id="bibr11-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.H.</given-names></name>
<name><surname>Chiou</surname><given-names>H.Y.</given-names></name>
<name><surname>Lin</surname><given-names>H.C.</given-names></name>
<name><surname>Lin</surname><given-names>H.L.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Affect of seizures during gestation on pregnancy outcomes in women with epilepsy</article-title>. <source>Arch Neurol</source> <volume>66</volume>: <fpage>979</fpage>–<lpage>984</lpage>.</citation>
</ref>
<ref id="bibr12-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Craciunescu</surname><given-names>C.N.</given-names></name>
<name><surname>Brown</surname><given-names>E.C.</given-names></name>
<name><surname>Mar</surname><given-names>M.H.</given-names></name>
<name><surname>Albright</surname><given-names>C.D.</given-names></name>
<name><surname>Nadeau</surname><given-names>M.R.</given-names></name>
<name><surname>Zeisel</surname><given-names>S.H.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Folic acid deficiency during late gestation decreases progenitor cell proliferation and increases apoptosis in fetal mouse brain</article-title>. <source>J Nutr</source> <volume>134</volume>: <fpage>162</fpage>–<lpage>166</lpage>.</citation>
</ref>
<ref id="bibr13-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deave</surname><given-names>T.</given-names></name>
<name><surname>Heron</surname><given-names>J.</given-names></name>
<name><surname>Evans</surname><given-names>J.</given-names></name>
<name><surname>Emond</surname><given-names>A.</given-names></name>
</person-group> (<year>2008</year>) <article-title>The impact of maternal depression in pregnancy on early child development</article-title>. <source>BJOG</source> <volume>115</volume>: <fpage>1043</fpage>–<lpage>1051</lpage>.</citation>
</ref>
<ref id="bibr14-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dolk</surname><given-names>H.</given-names></name>
<name><surname>Jentink</surname><given-names>J.</given-names></name>
<name><surname>Loane</surname><given-names>M.</given-names></name>
<name><surname>Morris</surname><given-names>J.</given-names></name>
<name><surname>de Jong-van den Berg</surname><given-names>L.T.</given-names></name>
</person-group> (<year>2008</year>) <article-title>EUROCAT Antiepileptic Drug Working Group. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations?</article-title> <source>Neurology</source> <volume>71</volume>: <fpage>714</fpage>–<lpage>722</lpage>.</citation>
</ref>
<ref id="bibr15-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dolovich</surname><given-names>L.R.</given-names></name>
<name><surname>Addis</surname><given-names>A.</given-names></name>
<name><surname>Vaillancourt</surname><given-names>J.M.</given-names></name>
<name><surname>Power</surname><given-names>J.D.</given-names></name>
<name><surname>Koren</surname><given-names>G.</given-names></name>
<name><surname>Einarson</surname><given-names>T.R.</given-names></name>
</person-group> (<year>1998</year>) <article-title>Benzodiazepine use in pregnancy and major malformations or oral clefts: meta-analysis of cohort and case-control studies</article-title>. <source>BMJ</source> <volume>317</volume>: <fpage>839</fpage>–<lpage>843</lpage>.</citation>
</ref>
<ref id="bibr16-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eriksson</surname><given-names>K.</given-names></name>
<name><surname>Viinikainen</surname><given-names>K.</given-names></name>
<name><surname>Mönkkönen</surname><given-names>A.</given-names></name>
<name><surname>Äikiä</surname><given-names>M.</given-names></name>
<name><surname>Nieminen</surname><given-names>P.</given-names></name>
<name><surname>Heinonen</surname><given-names>S.</given-names></name>
<name><surname>Kälviäinen</surname><given-names>R.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Children exposed to valproate in utero – population based evaluation of risks and confounding factors for long-term neurocognitive development</article-title>. <source>Epilepsy Res</source> <volume>65</volume>: <fpage>189</fpage>–<lpage>200</lpage>.</citation>
</ref>
<ref id="bibr17-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eros</surname><given-names>E.</given-names></name>
<name><surname>Czeizel</surname><given-names>A.E.</given-names></name>
<name><surname>Rockenbauer</surname><given-names>M.</given-names></name>
<name><surname>Sorensen</surname><given-names>H.T.</given-names></name>
<name><surname>Olsen</surname><given-names>J.</given-names></name>
</person-group> (<year>2002</year>) <article-title>A population-based case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolam and clonazepam treatment during pregnancy</article-title>. <source>Eur J Obstet Gynaecol Reprod Biol</source> <volume>101</volume>: <fpage>147</fpage>–<lpage>154</lpage>.</citation>
</ref>
<ref id="bibr18-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ettinger</surname><given-names>A.</given-names></name>
<name><surname>Reed</surname><given-names>M.</given-names></name>
<name><surname>Cramer</surname><given-names>J.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Epilepsy Impact Project Group. Depression and comorbidity in community-based patients with epilepsy or asthma</article-title>. <source>Neurology</source> <volume>63</volume>: <fpage>1008</fpage>–<lpage>1014</lpage>.</citation>
</ref>
<ref id="bibr19-2042098611433192">
<citation citation-type="journal">
<collab>EURAP</collab> (<year>2006</year>) <article-title>Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry</article-title>. <source>Neurology</source> <volume>66</volume>: <fpage>354</fpage>–<lpage>360</lpage>.</citation>
</ref>
<ref id="bibr20-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Farwell</surname><given-names>J.R.</given-names></name>
<name><surname>Young</surname><given-names>J.L.</given-names></name>
<name><surname>Hirtz</surname><given-names>D.G.</given-names></name>
<name><surname>Sulzbacher</surname><given-names>S.I.</given-names></name>
<name><surname>Ellenberg</surname><given-names>J.H.</given-names></name>
<name><surname>Nelson</surname><given-names>K.B.</given-names></name>
</person-group> (<year>1990</year>) <article-title>Phenobarbital for febrile seizures – effects on intelligence and on seizure recurrence</article-title>. <source>N Engl J Med</source> <volume>322</volume>: <fpage>364</fpage>–<lpage>369</lpage>.</citation>
</ref>
<ref id="bibr21-2042098611433192">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Finnell</surname><given-names>R.H.</given-names></name>
<name><surname>Chernoff</surname><given-names>G.F.</given-names></name>
</person-group> (<year>1987</year>) <article-title>Gene-teratogen interactions. An approach to understanding the metabolic basis of birth defects</article-title>. In: <person-group person-group-type="editor">
<name><surname>Nau</surname><given-names>H.</given-names></name>
<name><surname>Scott</surname><given-names>W.J.</given-names></name>
</person-group> (eds), <source>Pharmacokinetics in Teratogenesis</source>. <publisher-loc>Boca Raton, FL</publisher-loc>: <publisher-name>CRC Press, pp</publisher-name>. <fpage>97</fpage>–<lpage>109</lpage>.</citation>
</ref>
<ref id="bibr22-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gaily</surname><given-names>E.</given-names></name>
<name><surname>Kantola-Sorsa</surname><given-names>E.</given-names></name>
<name><surname>Granstrom</surname><given-names>M.L.</given-names></name>
</person-group> (<year>1988</year>) <article-title>Intelligence of children of epileptic mothers</article-title>. <source>J Pediatr</source> <volume>113</volume>: <fpage>677</fpage>–<lpage>684</lpage>.</citation>
</ref>
<ref id="bibr23-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gaily</surname><given-names>E.</given-names></name>
<name><surname>Kantola-Sorsa</surname><given-names>E.</given-names></name>
<name><surname>Hiilesmaa</surname><given-names>V.</given-names></name>
<name><surname>Isoaho</surname><given-names>M.</given-names></name>
<name><surname>Matila</surname><given-names>R.</given-names></name>
<name><surname>Kotila</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Normal intelligence in children with prenatal exposure to carbamazepine</article-title>. <source>Neurology</source>; <volume>62</volume>(<issue>1</issue>):<fpage>28</fpage>-<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr24-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Galanti</surname><given-names>M.</given-names></name>
<name><surname>Newport</surname><given-names>D.J.</given-names></name>
<name><surname>Pennell</surname><given-names>P.B.</given-names></name>
<name><surname>Titchner</surname><given-names>D.</given-names></name>
<name><surname>Newman</surname><given-names>M.</given-names></name>
<name><surname>Knight</surname><given-names>B.T.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Postpartum depression in women with epilepsy: influence of antiepileptic drugs in a prospective study</article-title>. <source>Epilepsy Behav</source> <volume>16</volume>: <fpage>426</fpage>–<lpage>430</lpage>.</citation>
</ref>
<ref id="bibr25-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Glier</surname><given-names>C.</given-names></name>
<name><surname>Dzietko</surname><given-names>M.</given-names></name>
<name><surname>Bittigau</surname><given-names>P.</given-names></name>
<name><surname>Jarosz</surname><given-names>B.</given-names></name>
<name><surname>Korobowicz</surname><given-names>E.</given-names></name>
<name><surname>Ikonomidou</surname><given-names>C.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Therapeutic doses of topiramate are not toxic to the developing rat brain</article-title>. <source>Exp Neurol</source> <volume>187</volume>: <fpage>403</fpage>–<lpage>409</lpage>.</citation>
</ref>
<ref id="bibr26-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hanson</surname><given-names>J.W.</given-names></name>
<name><surname>Myrianthopoulos</surname><given-names>N.C.</given-names></name>
<name><surname>Harvey</surname><given-names>M.A.</given-names></name>
<name><surname>Smith</surname><given-names>D.W.</given-names></name>
</person-group> (<year>1976</year>) <article-title>Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome</article-title>. <source>J Pediatr</source> <volume>89</volume>: <fpage>662</fpage>–<lpage>668</lpage>.</citation>
</ref>
<ref id="bibr27-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harden</surname><given-names>C.L.</given-names></name>
<name><surname>Hopp</surname><given-names>J.</given-names></name>
<name><surname>Ting</surname><given-names>T.Y.</given-names></name>
<name><surname>Pennell</surname><given-names>P.B.</given-names></name>
<name><surname>French</surname><given-names>J.A.</given-names></name>
<name><surname>Allen Hauser</surname><given-names>W.</given-names></name>
</person-group> (<year>2009a</year>) <article-title>Practice parameter update: management issues for women with epilepsy – focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society</article-title>. <source>Neurology</source> <volume>73</volume>: <fpage>126</fpage>–<lpage>132</lpage>.</citation>
</ref>
<ref id="bibr28-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harden</surname><given-names>C.L.</given-names></name>
<name><surname>Meador</surname><given-names>K.J.</given-names></name>
<name><surname>Pennell</surname><given-names>P.B.</given-names></name>
<name><surname>Hauser</surname><given-names>W.A.</given-names></name>
<name><surname>Gronseth</surname><given-names>G.S.</given-names></name>
<name><surname>French</surname><given-names>J.A.</given-names></name>
</person-group> (<year>2009b</year>) <article-title>Practice parameter update: management issues for women with epilepsy – focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes. Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and American Epilepsy Society</article-title>. <source>Neurology</source> <volume>73</volume>: <fpage>133</fpage>–<lpage>141</lpage>.</citation>
</ref>
<ref id="bibr29-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harden</surname><given-names>C.L.</given-names></name>
<name><surname>Pennell</surname><given-names>P.B.</given-names></name>
<name><surname>Koppel</surname><given-names>B.S.</given-names></name>
<name><surname>Hovinga</surname><given-names>C.A.</given-names></name>
<name><surname>Gidal</surname><given-names>B.</given-names></name>
<name><surname>Meador</surname><given-names>K.J.</given-names></name>
<etal/>
</person-group>. (<year>2009c</year>) <article-title>Practice parameter update: management issues for women with epilepsy – focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society</article-title>. <source>Neurology</source> <volume>73</volume>: <fpage>142</fpage>–<lpage>149</lpage>.</citation>
</ref>
<ref id="bibr30-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hay</surname><given-names>D.F.</given-names></name>
<name><surname>Pawlby</surname><given-names>S.</given-names></name>
<name><surname>Waters</surname><given-names>C.S.</given-names></name>
<name><surname>Sharp</surname><given-names>D.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Antepartum and postpartum exposure to maternal depression: different effects on different adolescent outcomes</article-title>. <source>J Child Psychol Psychiatry</source> <volume>49</volume>: <fpage>1079</fpage>–<lpage>1088</lpage>.</citation>
</ref>
<ref id="bibr31-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hirtz</surname><given-names>D.</given-names></name>
<name><surname>Thurman</surname><given-names>D.J.</given-names></name>
<name><surname>Gwinn-Hardy</surname><given-names>K.</given-names></name>
<name><surname>Mohamed</surname><given-names>M.</given-names></name>
<name><surname>Chaudhuri</surname><given-names>A.R.</given-names></name>
<name><surname>Zalutsky</surname><given-names>R.</given-names></name>
</person-group> (<year>2007</year>) <article-title>How common are the “common” neurologic disorders?</article-title> <source>Neurology</source> <volume>68</volume>: <fpage>326</fpage>–<lpage>337</lpage>.</citation>
</ref>
<ref id="bibr32-2042098611433192">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Hiilesman</surname><given-names>V.</given-names></name>
</person-group> (<year>1996</year>) <article-title>Effects of maternal seizures on the fetus</article-title>. In: <person-group person-group-type="editor">
<name><surname>Tomson</surname><given-names>T.</given-names></name>
<name><surname>Gram</surname><given-names>L.</given-names></name>
<name><surname>Sillanpää</surname><given-names>M.</given-names></name>
<name><surname>Johannesen</surname><given-names>S.</given-names></name>
</person-group> (eds), <source>Epilepsy and Pregnancy</source>. <publisher-loc>Peterfield, UK and Bristol, PA, USA</publisher-loc>: <publisher-name>Wrightson Biomedical Publishing Ltd, pp</publisher-name>. <fpage>135</fpage>–<lpage>141</lpage>.</citation>
</ref>
<ref id="bibr33-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holmes</surname><given-names>L.B.</given-names></name>
<name><surname>Mittendorf</surname><given-names>R.</given-names></name>
<name><surname>Shen</surname><given-names>A.</given-names></name>
<name><surname>Smith</surname><given-names>C.R.</given-names></name>
<name><surname>Hernandez-Diaz</surname><given-names>S.</given-names></name>
</person-group> <collab>Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations</collab> (<year>2011</year>). <source>Arch Neurol</source> <volume>68</volume>(<issue>10</issue>):<fpage>1275</fpage>-<lpage>81</lpage>. <comment>Epub 2011 Jun 13</comment>.</citation>
</ref>
<ref id="bibr34-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holmes</surname><given-names>L.B.</given-names></name>
<name><surname>Wyszynski</surname><given-names>D.F.</given-names></name>
</person-group> (<year>2004</year>) <article-title>North American antiepileptic drug pregnancy registry</article-title>. <source>Epilepsia</source> <volume>45</volume>: <fpage>1465</fpage>.</citation>
</ref>
<ref id="bibr35-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holmes</surname><given-names>L.B.</given-names></name>
<name><surname>Wyszynski</surname><given-names>D.F.</given-names></name>
<name><surname>Baldwin</surname><given-names>E.J.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Increased risk for non-syndromic cleft palate among infants exposed to lamotrigine during pregnancy</article-title>. <source>Birth Def Res (Part A): Clin Mol Teratol</source> <volume>76</volume>: <fpage>318</fpage>.</citation>
</ref>
<ref id="bibr36-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holmes</surname><given-names>L.B.</given-names></name>
<name><surname>Wyszynski</surname><given-names>D.F.</given-names></name>
<name><surname>Lieberman</surname><given-names>E.</given-names></name>
</person-group> (<year>2004</year>) <article-title>The AED (antiepileptic drug) pregnancy registry: a 6-year experience</article-title>. <source>Arch Neurol</source> <volume>61</volume>: <fpage>673</fpage>–<lpage>678</lpage>.</citation>
</ref>
<ref id="bibr37-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holmes</surname><given-names>L.B.</given-names></name>
<name><surname>Rosenberger</surname><given-names>P.B.</given-names></name>
<name><surname>Harvey</surname><given-names>E.A.</given-names></name>
<name><surname>Khoshbin</surname><given-names>S.</given-names></name>
<name><surname>Ryan</surname><given-names>L.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Intelligence and physical features of children of women with epilepsy</article-title>. <source>Teratology</source> <volume>61</volume>(<issue>3</issue>):<fpage>196</fpage>–<lpage>202</lpage>.</citation>
</ref>
<ref id="bibr38-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Horwitz</surname><given-names>S.M.</given-names></name>
<name><surname>Briggs-Gowan</surname><given-names>M.J.</given-names></name>
<name><surname>Storfer-Isser</surname><given-names>A.</given-names></name>
<name><surname>Carter</surname><given-names>A.S.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Prevalence, correlates, and persistence of maternal depression</article-title>. <source>J Womens Health (Larchmt)</source> <volume>16</volume>: <fpage>678</fpage>–<lpage>691</lpage>.</citation>
</ref>
<ref id="bibr39-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hunt</surname><given-names>S.</given-names></name>
<name><surname>Craig</surname><given-names>J.</given-names></name>
<name><surname>Russell</surname><given-names>A.</given-names></name>
<name><surname>Guthrie</surname><given-names>E.</given-names></name>
<name><surname>Parsons</surname><given-names>L.</given-names></name>
<name><surname>Robertson</surname><given-names>I.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register</article-title>. <source>Neurology</source> <volume>67</volume>: <fpage>1876</fpage>–<lpage>1879</lpage>.</citation>
</ref>
<ref id="bibr40-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hunt</surname><given-names>S.</given-names></name>
<name><surname>Russell</surname><given-names>A.</given-names></name>
<name><surname>Smithson</surname><given-names>W.H.</given-names></name>
<name><surname>Parsons</surname><given-names>L.</given-names></name>
<name><surname>Robertson</surname><given-names>I.</given-names></name>
<name><surname>Waddell</surname><given-names>R.</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>UK Epilepsy and Pregnancy Register. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register</article-title>. <source>Neurology</source> <volume>71</volume>: <fpage>272</fpage>–<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr41-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hvas</surname><given-names>C.L.</given-names></name>
<name><surname>Henriksen</surname><given-names>T.B.</given-names></name>
<name><surname>Ostergaard</surname><given-names>J.R.</given-names></name>
<name><surname>Dam</surname><given-names>M.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Epilepsy and pregnancy: effect of antiepileptic drugs and lifestyle on birth weight</article-title>. <source>Br J Obstet Gynaecol</source> <volume>107</volume>: <fpage>896</fpage>–<lpage>902</lpage>.</citation>
</ref>
<ref id="bibr42-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ikonomidou</surname><given-names>C.</given-names></name>
<name><surname>Bittigau</surname><given-names>P.</given-names></name>
<name><surname>Ishimaru</surname><given-names>M.J.</given-names></name>
<name><surname>Wozniak</surname><given-names>D.F.</given-names></name>
<name><surname>Koch</surname><given-names>C.</given-names></name>
<name><surname>Genz</surname><given-names>K.</given-names></name>
<etal/>
</person-group>. (<year>2000</year>) <article-title>Ethanol-induced apoptotic neurodegeneration and fetal alcohol syndrome</article-title>. <source>Science</source> <volume>287</volume>: <fpage>1056</fpage>–<lpage>1060</lpage>.</citation>
</ref>
<ref id="bibr43-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ikonomidou</surname><given-names>C.</given-names></name>
<name><surname>Turski</surname><given-names>L.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Antiepileptic drugs and brain development</article-title>. <source>Epilepsy Res</source> <volume>88</volume>: <fpage>11</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr44-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jentink</surname><given-names>J.</given-names></name>
<name><surname>Bakker</surname><given-names>M.K.</given-names></name>
<name><surname>Nijenhuis</surname><given-names>C.M.</given-names></name>
<name><surname>Wilffert</surname><given-names>B.</given-names></name>
<name><surname>de Jong-van den Berg</surname><given-names>L.T.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Dose folic acid use decrease the risk for spina bifida after in utero exposure to valproic acid?</article-title> <source>Pharmacoepidemiol Drug Saf</source> <volume>19</volume>: <fpage>803</fpage>–<lpage>807</lpage>.</citation>
</ref>
<ref id="bibr45-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jentink</surname><given-names>J.</given-names></name>
<name><surname>Dolk</surname><given-names>H.</given-names></name>
<name><surname>Loane</surname><given-names>M.A.</given-names></name>
<name><surname>Morris</surname><given-names>J.K.</given-names></name>
<name><surname>Wellesley</surname><given-names>D.</given-names></name>
<name><surname>Garne</surname><given-names>E.</given-names></name>
<name><surname>de Jong-van den Berg</surname><given-names>L.</given-names></name>
</person-group> (<year>2010a</year>) <article-title>EUROCAT Antiepileptic Study Working Group. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study</article-title>. <source>BMJ</source> <volume>341</volume>: <fpage>c6581</fpage>.</citation>
</ref>
<ref id="bibr46-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jentink</surname><given-names>J.</given-names></name>
<name><surname>Loane</surname><given-names>M.A.</given-names></name>
<name><surname>Dolk</surname><given-names>H.</given-names></name>
<name><surname>Barisic</surname><given-names>I.</given-names></name>
<name><surname>Garne</surname><given-names>E.</given-names></name>
<name><surname>Morris</surname><given-names>J.K.</given-names></name>
<name><surname>de Jong-van den Berg</surname><given-names>L.T.</given-names></name>
</person-group> (<year>2010b</year>) <article-title>EUROCAT Antiepileptic Study Working Group. Valproic acid monotherapy in pregnancy and major congenital malformations</article-title>. <source>N Engl J Med</source> <volume>362</volume>: <fpage>2185</fpage>–<lpage>2193</lpage>.</citation>
</ref>
<ref id="bibr47-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaaja</surname><given-names>E.</given-names></name>
<name><surname>Kaaja</surname><given-names>R.</given-names></name>
<name><surname>Hiilesmaa</surname><given-names>V.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Major malformations in offspring of women with epilepsy</article-title>. <source>Neurology</source> <volume>60</volume>: <fpage>575</fpage>–<lpage>579</lpage>.</citation>
</ref>
<ref id="bibr48-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Katz</surname><given-names>I.</given-names></name>
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Gale</surname><given-names>K.</given-names></name>
<name><surname>Kondratyev</surname><given-names>A.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Effects of lamotrigine alone and in combination with MK-801, phenobarbital, or phenytoin on cell death in the neonatal rat brain</article-title>. <source>J Pharmacol Exp Ther</source> <volume>322</volume>: <fpage>494</fpage>–<lpage>500</lpage>.</citation>
</ref>
<ref id="bibr49-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kelly</surname><given-names>V.M.</given-names></name>
<name><surname>Nelson</surname><given-names>L.M.</given-names></name>
<name><surname>Chakravarty</surname><given-names>E.F.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Obstetric outcomes in women with multiple sclerosis and epilepsy</article-title>. <source>Neurology</source> <volume>73</volume>: <fpage>1831</fpage>–<lpage>1836</lpage>.</citation>
</ref>
<ref id="bibr50-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Kondratyev</surname><given-names>A.</given-names></name>
<name><surname>Gale</surname><given-names>K.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Antiepileptic drug-induced neuronal cell death in the immature brain: effects of carbamazepine, topiramate, and levetiracetam as monotherapy <italic>versus</italic> polytherapy</article-title>. <source>J Pharmacol Exp Ther</source> <volume>323</volume>: <fpage>165</fpage>–<lpage>173</lpage>.</citation>
</ref>
<ref id="bibr51-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koch</surname><given-names>S.</given-names></name>
<name><surname>Titze</surname><given-names>K.</given-names></name>
<name><surname>Zimmermann</surname><given-names>R.B.</given-names></name>
<name><surname>Schröder</surname><given-names>M.</given-names></name>
<name><surname>Lehmkuhl</surname><given-names>U.</given-names></name>
<name><surname>Rauh</surname><given-names>H.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents</article-title>. <source>Epilepsia</source> <volume>40</volume>: <fpage>1237</fpage>–<lpage>1243</lpage>.</citation>
</ref>
<ref id="bibr52-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Laegreid</surname><given-names>L.</given-names></name>
<name><surname>Olegard</surname><given-names>R.</given-names></name>
<name><surname>Conradi</surname><given-names>N.</given-names></name>
<name><surname>Hagberg</surname><given-names>G.</given-names></name>
<name><surname>Wahlström</surname><given-names>J.</given-names></name>
<name><surname>Abrahamsson</surname><given-names>L.</given-names></name>
</person-group> (<year>1990</year>) <article-title>Congenital malformations and maternal consumption of benzodiazepines: a case-control study</article-title>. <source>Dev Med Child Neurol</source> <volume>32</volume>: <fpage>432</fpage>–<lpage>441</lpage>.</citation>
</ref>
<ref id="bibr53-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Laegreid</surname><given-names>L.</given-names></name>
<name><surname>Olegard</surname><given-names>R.</given-names></name>
<name><surname>Walstrom</surname><given-names>J.</given-names></name>
<name><surname>Conradi</surname><given-names>N.</given-names></name>
</person-group> (<year>1989</year>) <article-title>Teratogenic effects of benzodiazepine use during pregnancy</article-title>. <source>J Pediatr</source> <volume>114</volume>: <fpage>126</fpage>–<lpage>131</lpage>.</citation>
</ref>
<ref id="bibr54-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Loring</surname><given-names>D.W.</given-names></name>
<name><surname>Meador</surname><given-names>K.J.</given-names></name>
<name><surname>Thompson</surname><given-names>W.O.</given-names></name>
</person-group> (<year>1994</year>) <article-title>Neurodevelopment effects of phenytoin and carbamazepine</article-title>. <source>JAMA</source> <volume>272</volume>: <fpage>850</fpage>–<lpage>851</lpage>.</citation>
</ref>
<ref id="bibr55-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lösche</surname><given-names>G.</given-names></name>
<name><surname>Steinhausen</surname><given-names>H.C.</given-names></name>
<name><surname>Koch</surname><given-names>S.</given-names></name>
<name><surname>Helge</surname><given-names>H.</given-names></name>
</person-group> (<year>1994</year>) <article-title>The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors</article-title>. <source>Acta Paediatr</source> <volume>83</volume>: <fpage>961</fpage>–<lpage>966</lpage>.</citation>
</ref>
<ref id="bibr56-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lundgren</surname><given-names>E.M.</given-names></name>
<name><surname>Tuvemo</surname><given-names>T.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Effects of being born small for gestational age on long-term intellectual performance</article-title>. <source>Best Pract Res Clin Endocrinol Metab</source> <volume>22</volume>(<issue>3</issue>):<fpage>477</fpage>–<lpage>88</lpage>. <comment>Review</comment>.</citation>
</ref>
<ref id="bibr57-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manent</surname><given-names>J.B.</given-names></name>
<name><surname>Jorquera</surname><given-names>I.</given-names></name>
<name><surname>Mazzucchelli</surname><given-names>I.</given-names></name>
<name><surname>Depaulis</surname><given-names>A.</given-names></name>
<name><surname>Perucca</surname><given-names>E.</given-names></name>
<name><surname>Ben-Ari</surname><given-names>Y.</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias</article-title>. <source>Epilepsia</source> <volume>48</volume>: <fpage>684</fpage>–<lpage>693</lpage>.</citation>
</ref>
<ref id="bibr58-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manthey</surname><given-names>D.</given-names></name>
<name><surname>Asimiadou</surname><given-names>S.</given-names></name>
<name><surname>Stefovska</surname><given-names>V.</given-names></name>
<name><surname>Kaindl</surname><given-names>A.M.</given-names></name>
<name><surname>Fassbender</surname><given-names>J.</given-names></name>
<name><surname>Ikonomidou</surname><given-names>C.</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brain</article-title>. <source>Exp Neurol</source> <volume>193</volume>: <fpage>497</fpage>–<lpage>503</lpage>.</citation>
</ref>
<ref id="bibr59-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mawer</surname><given-names>G.</given-names></name>
<name><surname>Briggs</surname><given-names>M.</given-names></name>
<name><surname>Baker</surname><given-names>G.A.</given-names></name>
<name><surname>Bromley</surname><given-names>R.</given-names></name>
<name><surname>Coyle</surname><given-names>H.</given-names></name>
<name><surname>Eatock</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study</article-title>. <source>Seizure</source> <volume>19</volume>: <fpage>112</fpage>–<lpage>119</lpage>.</citation>
</ref>
<ref id="bibr60-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meador</surname><given-names>K.J.</given-names></name>
<name><surname>Baker</surname><given-names>G.A.</given-names></name>
<name><surname>Browning</surname><given-names>N.</given-names></name>
<name><surname>Cohen</surname><given-names>M.J.</given-names></name>
<name><surname>Clayton-Smith</surname><given-names>J.</given-names></name>
<name><surname>Kalayjian</surname><given-names>L.A.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Foetal antiepileptic drug exposure and verbal <italic>versus</italic> non-verbal abilities at three years of age</article-title>. <source>Brain</source> <volume>134</volume>: <fpage>396</fpage>–<lpage>404</lpage>.</citation>
</ref>
<ref id="bibr61-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meador</surname><given-names>K.J.</given-names></name>
<name><surname>Baker</surname><given-names>G.A.</given-names></name>
<name><surname>Browning</surname><given-names>N.</given-names></name>
<name><surname>Clayton-Smith</surname><given-names>J.</given-names></name>
<name><surname>Coombs-Cantrell</surname><given-names>D.T.</given-names></name>
<name><surname>Cohen</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. <collab>for the NEAD Study Group</collab> (<year>2009</year>) <article-title>Fetal antiepileptic drug exposure and cognitive function at age 3</article-title>. <source>New Eng J Med</source> <volume>360</volume>: <fpage>1597</fpage>–<lpage>1605</lpage>.</citation>
</ref>
<ref id="bibr62-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meador</surname><given-names>K.J.</given-names></name>
<name><surname>Baker</surname><given-names>G.</given-names></name>
<name><surname>Cohen</surname><given-names>M.J.</given-names></name>
<name><surname>Gaily</surname><given-names>E.</given-names></name>
<name><surname>Westerveld</surname><given-names>M.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Cognitive/behavioral teratogenetic effects of antiepileptic drugs</article-title>. <source>Epilepsy Behav</source> <volume>11</volume>: <fpage>292</fpage>–<lpage>302</lpage>.</citation>
</ref>
<ref id="bibr63-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meador</surname><given-names>K.J.</given-names></name>
<name><surname>Pennell</surname><given-names>P.B.</given-names></name>
<name><surname>Harden</surname><given-names>C.L.</given-names></name>
<name><surname>Gordon</surname><given-names>J.C.</given-names></name>
<name><surname>Tomson</surname><given-names>T.</given-names></name>
<name><surname>Kaplan</surname><given-names>P.W.</given-names></name>
<etal/>
</person-group>. (<year>2008a</year>) <article-title>Pregnancy registries in epilepsy: a consensus statement on health outcomes</article-title>. <source>Neurology</source> <volume>71</volume>: <fpage>1109</fpage>–<lpage>1117</lpage>.</citation>
</ref>
<ref id="bibr64-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meador</surname><given-names>K.J.</given-names></name>
<name><surname>Reynolds</surname><given-names>R.W.</given-names></name>
<name><surname>Crean</surname><given-names>S.</given-names></name>
<name><surname>Fahrbach</surname><given-names>K.</given-names></name>
<name><surname>Probst</surname><given-names>C.</given-names></name>
</person-group> (<year>2008b</year>) <article-title>Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts</article-title>. <source>Epilepsy Res</source> <volume>81</volume>: <fpage>1</fpage>–<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr65-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meadow</surname><given-names>S.R.</given-names></name>
</person-group> (<year>1968</year>) <article-title>Anticonvulsant drugs and congenital abnormalities</article-title>. <source>Lancet</source> <volume>292</volume>: <fpage>1296</fpage>.</citation>
</ref>
<ref id="bibr66-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Medina</surname><given-names>A.E.</given-names></name>
<name><surname>Krahe</surname><given-names>T.E.</given-names></name>
<name><surname>Coppola</surname><given-names>D.M.</given-names></name>
<name><surname>Ramoa</surname><given-names>A.S.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Neonatal alcohol exposure induces long-lasting impairment of visual cortical plasticity in ferrets</article-title>. <source>J Neurosci</source> <volume>23</volume>: <fpage>10002</fpage>–<lpage>10012</lpage>.</citation>
</ref>
<ref id="bibr67-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mølgaard-Nielsen</surname><given-names>D.</given-names></name>
<name><surname>Hviid</surname><given-names>A.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Newer-generation antiepileptic drugs and the risk of major birth defects</article-title>. <source>JAMA</source> <volume>305</volume>(<issue>19</issue>):<fpage>1996</fpage>–<lpage>2002</lpage>.</citation>
</ref>
<ref id="bibr68-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morrow</surname><given-names>J.I.</given-names></name>
<name><surname>Hunt</surname><given-names>S.J.</given-names></name>
<name><surname>Russell</surname><given-names>A.J.</given-names></name>
<name><surname>Smithson</surname><given-names>W.H.</given-names></name>
<name><surname>Parsons</surname><given-names>L.</given-names></name>
<name><surname>Robertson</surname><given-names>I.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Folic acid use and major congenital malformations in offspring of women with epilepsy: a prospective study from the UK Epilepsy and Pregnancy Register</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <volume>80</volume>: <fpage>506</fpage>–<lpage>511</lpage>.</citation>
</ref>
<ref id="bibr69-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morrow</surname><given-names>J.</given-names></name>
<name><surname>Russell</surname><given-names>A.</given-names></name>
<name><surname>Guthrie</surname><given-names>E.</given-names></name>
<name><surname>Parsons</surname><given-names>L.</given-names></name>
<name><surname>Robertson</surname><given-names>I.</given-names></name>
<name><surname>Waddell</surname><given-names>R.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Malformations risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <volume>77</volume>: <fpage>193</fpage>–<lpage>198</lpage>.</citation>
</ref>
<ref id="bibr70-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nadebaum</surname><given-names>C.</given-names></name>
<name><surname>Anderson</surname><given-names>V.</given-names></name>
<name><surname>Vajda</surname><given-names>F.</given-names></name>
<name><surname>Reutens</surname><given-names>D.</given-names></name>
<name><surname>Barton</surname><given-names>S.</given-names></name>
<name><surname>Wood</surname><given-names>A.</given-names></name>
</person-group> (<year>2011</year>) <article-title>The Australian Brain and Cognition and Antiepileptic Drugs Study: IQ in school-aged children exposed to sodium valproate and polytherapy</article-title>. <source>J Int Neuropsychol Soc</source> <volume>17</volume>: <fpage>133</fpage>–<lpage>142</lpage>.</citation>
</ref>
<ref id="bibr71-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Newport</surname><given-names>D.J.</given-names></name>
<name><surname>Levey</surname><given-names>L.C.</given-names></name>
<name><surname>Pennell</surname><given-names>P.B.</given-names></name>
<name><surname>Ragan</surname><given-names>K.</given-names></name>
<name><surname>Stowe</surname><given-names>Z.N.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Suicidal ideation in pregnancy: assessment and clinical implications</article-title>. <source>Arch Womens Ment Health</source> <volume>10</volume>: <fpage>181</fpage>–<lpage>187</lpage>.</citation>
</ref>
<ref id="bibr72-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Connor</surname><given-names>T.G.</given-names></name>
<name><surname>Heron</surname><given-names>J.</given-names></name>
<name><surname>Golding</surname><given-names>J.</given-names></name>
<name><surname>Glover</surname><given-names>V.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Maternal antenatal anxiety and behavioural/emotional problems in children: a test of a programming hypothesis</article-title>. <source>J Child Psychol Psychiatry</source> <volume>44</volume>: <fpage>1025</fpage>–<lpage>1036</lpage>.</citation>
</ref>
<ref id="bibr73-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ogura</surname><given-names>H.</given-names></name>
<name><surname>Yasuda</surname><given-names>M.</given-names></name>
<name><surname>Nakamura</surname><given-names>S.</given-names></name>
<name><surname>Yamashita</surname><given-names>H.</given-names></name>
<name><surname>Mikoshiba</surname><given-names>K.</given-names></name>
<name><surname>Ohmori</surname><given-names>H.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Neurotoxic damage of granule cells in the dentate gyrus and the cerebellum and cognitive deficit following neonatal administration of phenytoin in mice</article-title>. <source>J Neuropathol Exp Neurol</source> <volume>61</volume>: <fpage>956</fpage>–<lpage>967</lpage>.</citation>
</ref>
<ref id="bibr74-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Palac</surname><given-names>S.</given-names></name>
<name><surname>Meador</surname><given-names>K.J.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Antiepileptic drugs and neurodevelopment: an update</article-title>. <source>Curr Neurol Neurosci Rep</source> <volume>11</volume> (<issue>in press</issue>).</citation>
</ref>
<ref id="bibr75-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pennell</surname><given-names>P.B.</given-names></name>
<name><surname>Hovinga</surname><given-names>C.A.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Antiepileptic drug therapy in pregnancy I: gestation-induced effects on AED pharmacokinetics</article-title>. <source>Int Rev Neurobiol</source> <volume>83</volume>: <fpage>227</fpage>–<lpage>240</lpage>.</citation>
</ref>
<ref id="bibr76-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pennell</surname><given-names>P.B.</given-names></name>
<name><surname>Peng</surname><given-names>L.</given-names></name>
<name><surname>Newport</surname><given-names>D.J.</given-names></name>
<name><surname>Ritchie</surname><given-names>J.C.</given-names></name>
<name><surname>Koganti</surname><given-names>A.</given-names></name>
<name><surname>Holley</surname><given-names>D.K.</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency</article-title>. <source>Neurology</source> <volume>70</volume>: <fpage>2130</fpage>–<lpage>2136</lpage>.</citation>
</ref>
<ref id="bibr77-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pennell</surname><given-names>P.B.</given-names></name>
<name><surname>Newport</surname><given-names>D.J.</given-names></name>
<name><surname>Stow</surname><given-names>Z.N.</given-names></name>
<name><surname>Helmers</surname><given-names>S.L.</given-names></name>
<name><surname>Montgomery</surname><given-names>J.Q.</given-names></name>
<name><surname>Henry</surname><given-names>T.R.</given-names></name>
</person-group> (<year>2004</year>) <article-title>The impact of pregnancy and childbirth on the metabolism of lamotrigine</article-title>. <source>Neurology</source> <volume>62</volume>: <fpage>292</fpage>–<lpage>295</lpage>.</citation>
</ref>
<ref id="bibr78-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Petrenaite</surname><given-names>V.</given-names></name>
<name><surname>Sabers</surname><given-names>A.</given-names></name>
<name><surname>Hansen-Schwartz</surname><given-names>J.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Individual changes in lamotrigine plasma concentrations during pregnancy</article-title>. <source>Epilepsy Res</source> <volume>65</volume>: <fpage>185</fpage>–<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr79-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Petrenaite</surname><given-names>V.</given-names></name>
<name><surname>Sabers</surname><given-names>A.</given-names></name>
<name><surname>Hansen-Schwartz</surname><given-names>J.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Seizure deterioration in women treated with oxcarbazepine during pregnancy</article-title>. <source>Epilepsy Res</source> <volume>84</volume>: <fpage>245</fpage>–<lpage>249</lpage>.</citation>
</ref>
<ref id="bibr80-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rasalam</surname><given-names>A.D.</given-names></name>
<name><surname>Hailey</surname><given-names>H.</given-names></name>
<name><surname>Williams</surname><given-names>L.H.G.</given-names></name>
<name><surname>Moore</surname><given-names>S.J.</given-names></name>
<name><surname>Turnpenny</surname><given-names>P.D.</given-names></name>
<name><surname>Lloyd</surname><given-names>D.J.</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Characteristics of fetal anticonvulsant syndrome associated autistic disorder</article-title>. <source>Dev Med Child Neurol</source> <volume>47</volume>: <fpage>551</fpage>–<lpage>555</lpage>.</citation>
</ref>
<ref id="bibr81-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reinisch</surname><given-names>J.M.</given-names></name>
<name><surname>Sanders</surname><given-names>S.A.</given-names></name>
<name><surname>Mortensen</surname><given-names>E.L.</given-names></name>
<name><surname>Rubin</surname><given-names>D.B.</given-names></name>
</person-group> (<year>1995</year>) <article-title>In utero exposure to phenobarbital and intelligence deficits in adult men</article-title>. <source>JAMA</source> <volume>274</volume>: <fpage>1518</fpage>–<lpage>1525</lpage>.</citation>
</ref>
<ref id="bibr82-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sabers</surname><given-names>A.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Influences on seizure activity in pregnant women with epilepsy</article-title>. <source>Epilepsy Behav</source> <volume>15</volume>: <fpage>230</fpage>–<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr83-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sabers</surname><given-names>A.</given-names></name>
<name><surname>Petrenaite</surname><given-names>V.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Seizure frequency in pregnant women treated with lamotrigine monotherapy</article-title>. <source>Epilepsia</source> <volume>50</volume>: <fpage>2163</fpage>–<lpage>2166</lpage>.</citation>
</ref>
<ref id="bibr84-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scolnik</surname><given-names>D.</given-names></name>
<name><surname>Nulman</surname><given-names>I.</given-names></name>
<name><surname>Rovet</surname><given-names>J.</given-names></name>
<name><surname>Gladstone</surname><given-names>D.</given-names></name>
<name><surname>Czuchta</surname><given-names>D.</given-names></name>
<name><surname>Gardner</surname><given-names>H.A.</given-names></name>
<etal/>
</person-group>. (<year>1994</year>) <article-title>Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy</article-title>. <source>JAMA</source> <volume>271</volume>: <fpage>767</fpage>–<lpage>770</lpage>.</citation>
</ref>
<ref id="bibr85-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shallcross</surname><given-names>R.</given-names></name>
<name><surname>Bromley</surname><given-names>R.L.</given-names></name>
<name><surname>Irwin</surname><given-names>B.</given-names></name>
<name><surname>Bonnett</surname><given-names>L.J.</given-names></name>
<name><surname>Morrow</surname><given-names>J.</given-names></name>
<name><surname>Baker</surname><given-names>G.A.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Liverpool Manchester Neurodevelopment Group; UK Epilepsy and Pregnancy Register. Child development following in utero exposure: levetiracetam vs. sodium valproate</article-title>. <source>Neurology</source> <volume>76</volume>: <fpage>383</fpage>–<lpage>399</lpage>.</citation>
</ref>
<ref id="bibr86-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shapiro</surname><given-names>S.</given-names></name>
<name><surname>Hartz</surname><given-names>S.C.</given-names></name>
<name><surname>Siskind</surname><given-names>V.</given-names></name>
<name><surname>Mitchell</surname><given-names>A.A.</given-names></name>
<name><surname>Slone</surname><given-names>D.</given-names></name>
<name><surname>Rosenberg</surname><given-names>L.</given-names></name>
<etal/>
</person-group>. (<year>1976</year>) <article-title>Anticonvulsants and parental epilepsy in the development of birth defects</article-title>. <source>Lancet</source> <volume>1</volume>: <fpage>272</fpage>–<lpage>275</lpage>.</citation>
</ref>
<ref id="bibr87-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stefovska</surname><given-names>V.G.</given-names></name>
<name><surname>Uckermann</surname><given-names>O.</given-names></name>
<name><surname>Czuczwar</surname><given-names>M.</given-names></name>
<name><surname>Smitka</surname><given-names>M.</given-names></name>
<name><surname>Czuczwar</surname><given-names>P.</given-names></name>
<name><surname>Kis</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Sedative and anticonvulsant drugs suppress postnatal neurogenesis</article-title>. <source>Ann Neurol</source> <volume>64</volume>: <fpage>434</fpage>–<lpage>445</lpage>.</citation>
</ref>
<ref id="bibr88-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>St Louis</surname><given-names>E.K.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Monitoring antiepileptic drugs: a level-headed approach</article-title>. <source>Curr Neuropharmacol</source> <volume>7</volume>: <fpage>115</fpage>–<lpage>119</lpage>.</citation>
</ref>
<ref id="bibr89-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tamura</surname><given-names>T.</given-names></name>
<name><surname>Goldenberg</surname><given-names>R.L.</given-names></name>
<name><surname>Chapman</surname><given-names>V.R.</given-names></name>
<name><surname>Johnston</surname><given-names>K.E.</given-names></name>
<name><surname>Ramey</surname><given-names>S.L.</given-names></name>
<name><surname>Nelson</surname><given-names>K.G.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Folate status of mothers during pregnancy and mental and psychomotor development of their children at five years of age</article-title>. <source>Pediatrics</source> <volume>116</volume>: <fpage>703</fpage>–<lpage>708</lpage>.</citation>
</ref>
<ref id="bibr90-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tomson</surname><given-names>T.</given-names></name>
<name><surname>Battino</surname><given-names>D.</given-names></name>
<name><surname>Bonizzoni</surname><given-names>E.</given-names></name>
<name><surname>Craig</surname><given-names>J.</given-names></name>
<name><surname>Lindhout</surname><given-names>D.</given-names></name>
<name><surname>Sabers</surname><given-names>A.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry</article-title>. <source>Lancet Neurol</source> <volume>7</volume>: <fpage>609</fpage>–<lpage>617</lpage>.</citation>
</ref>
<ref id="bibr91-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tran</surname><given-names>T.A.</given-names></name>
<name><surname>Leppik</surname><given-names>I.E.</given-names></name>
<name><surname>Blesi</surname><given-names>K.</given-names></name>
<name><surname>Sathanandan</surname><given-names>S.T.</given-names></name>
<name><surname>Remmel</surname><given-names>R.</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>Lamotrigine clearance during pregnancy</article-title>. <source>Neurology</source> <volume>59</volume>: <fpage>252</fpage>–<lpage>255</lpage></citation>
</ref>
<ref id="bibr92-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Turner</surname><given-names>K.</given-names></name>
<name><surname>Piazzini</surname><given-names>A.</given-names></name>
<name><surname>Franza</surname><given-names>A.</given-names></name>
<name><surname>Fumarola</surname><given-names>C.</given-names></name>
<name><surname>Chifari</surname><given-names>R.</given-names></name>
<name><surname>Marconi</surname><given-names>A.M.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Postpartum depression in women with epilepsy <italic>versus</italic> women without epilepsy</article-title>. <source>Epilepsy Behav</source> <volume>9</volume>: <fpage>293</fpage>–<lpage>297</lpage>.</citation>
</ref>
<ref id="bibr93-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Turner</surname><given-names>K.</given-names></name>
<name><surname>Piazzini</surname><given-names>A.</given-names></name>
<name><surname>Franza</surname><given-names>A.</given-names></name>
<name><surname>Marconi</surname><given-names>A.M.</given-names></name>
<name><surname>Canger</surname><given-names>R.</given-names></name>
<name><surname>Canevini</surname><given-names>M.P.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Epilepsy and postpartum depression</article-title>. <source>Epilepsia</source> <volume>50</volume>(<supplement>Suppl. 1</supplement>): <fpage>24</fpage>–<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr94-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vajda</surname><given-names>F.</given-names></name>
<name><surname>Solinas</surname><given-names>C.</given-names></name>
<name><surname>Graham</surname><given-names>J.</given-names></name>
<name><surname>Hitchcock</surname><given-names>A.</given-names></name>
<name><surname>Eadie</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2006b</year>) <article-title>The case for lamotrigine monitoring in pregnancy</article-title>. <source>J Clin Neurosci</source> <volume>13</volume>: <fpage>103</fpage>–<lpage>104</lpage>.</citation>
</ref>
<ref id="bibr95-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vajda</surname><given-names>F.J.</given-names></name>
<name><surname>Hitchcock</surname><given-names>A.A.</given-names></name>
<name><surname>Graham</surname><given-names>J.</given-names></name>
<name><surname>O’Brien</surname><given-names>T.J.</given-names></name>
<name><surname>Lander</surname><given-names>C.M.</given-names></name>
<name><surname>Eadie</surname><given-names>M.J.</given-names></name>
</person-group> (<year>2010</year>) <article-title>The teratogenic risk of antiepileptic drug polytherapy</article-title>. <source>Epilepsia</source> <volume>51</volume>: <fpage>805</fpage>–<lpage>810</lpage>.</citation>
</ref>
<ref id="bibr96-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vajda</surname><given-names>F.J.</given-names></name>
<name><surname>Hitchcock</surname><given-names>A.A.</given-names></name>
<name><surname>Graham</surname><given-names>J.</given-names></name>
<name><surname>O’Brien</surname><given-names>T.</given-names></name>
<name><surname>Lander</surname><given-names>C.</given-names></name>
<name><surname>Eadie</surname><given-names>M.</given-names></name>
</person-group> (<year>2007a</year>) <article-title>The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies</article-title>. <source>Aust N Z J Obstet Gynaecol</source> <volume>76</volume>: <fpage>468</fpage>–<lpage>474</lpage>.</citation>
</ref>
<ref id="bibr97-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vajda</surname><given-names>F.J.</given-names></name>
<name><surname>Hitchcock</surname><given-names>A.</given-names></name>
<name><surname>Graham</surname><given-names>J.</given-names></name>
<name><surname>Solinas</surname><given-names>C.</given-names></name>
<name><surname>O’Brien</surname><given-names>T.J.</given-names></name>
<name><surname>Lander</surname><given-names>C.M.</given-names></name>
<etal/>
</person-group>. (<year>2006a</year>) <article-title>Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry</article-title>. <source>Eur J Neurol</source> <volume>13</volume>: <fpage>645</fpage>–<lpage>654</lpage>.</citation>
</ref>
<ref id="bibr98-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vajda</surname><given-names>F.J.</given-names></name>
<name><surname>Lander</surname><given-names>C.M.</given-names></name>
<name><surname>Hitchcock</surname><given-names>A.</given-names></name>
<name><surname>Graham</surname><given-names>J.</given-names></name>
<name><surname>Solinas</surname><given-names>C.</given-names></name>
<name><surname>O’Brien</surname><given-names>T.</given-names></name>
<name><surname>Eadie</surname><given-names>M.J.</given-names></name>
</person-group> (<year>2007b</year>) <article-title>Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences</article-title>. <source>J Clin Neurosci</source> <volume>14</volume>: <fpage>611</fpage>–<lpage>617</lpage>.</citation>
</ref>
<ref id="bibr99-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van den Bergh</surname><given-names>B.R.</given-names></name>
<name><surname>Mennes</surname><given-names>M.</given-names></name>
<name><surname>Oosterlaan</surname><given-names>J.</given-names></name>
<name><surname>Stevens</surname><given-names>V.</given-names></name>
<name><surname>Stiers</surname><given-names>P.</given-names></name>
<name><surname>Marcoen</surname><given-names>A.</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>High antenatal maternal anxiety is related to impulsivity during performance on cognitive tasks in 14- and 15-year-olds</article-title>. <source>Neurosci Biobehav Rev</source> <volume>29</volume>: <fpage>259</fpage>–<lpage>269</lpage>.</citation>
</ref>
<ref id="bibr100-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vanoverloop</surname><given-names>D.</given-names></name>
<name><surname>Schnell</surname><given-names>R.R.</given-names></name>
<name><surname>Harvey</surname><given-names>E.A.</given-names></name>
<name><surname>Holmes</surname><given-names>L.B.</given-names></name>
</person-group> (<year>1992</year>) <article-title>The effects of prenatal exposure to phenytoin and other anticonvulsants on intellectual function at 4 to 8 years of age</article-title>. <source>Neurotoxicol Teratol</source> <volume>14</volume>: <fpage>329</fpage>–<lpage>335</lpage>.</citation>
</ref>
<ref id="bibr101-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Veiby</surname><given-names>G.</given-names></name>
<name><surname>Daltveit</surname><given-names>A.K.</given-names></name>
<name><surname>Engelsen</surname><given-names>B.A.</given-names></name>
<name><surname>Gilhus</surname><given-names>N.E.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Pregnancy, delivery, and outcome for the child in maternal epilepsy</article-title>. <source>Epilepsia</source> <volume>50</volume>: <fpage>2130</fpage>–<lpage>2139</lpage>.</citation>
</ref>
<ref id="bibr102-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Viinikainen</surname><given-names>K.</given-names></name>
<name><surname>Heinonen</surname><given-names>S.</given-names></name>
<name><surname>Eriksson</surname><given-names>K.</given-names></name>
<name><surname>Kälviäinen</surname><given-names>R.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Community-based, prospective, controlled study of obstetric and neonatal outcomes of 179 pregnancies in women with epilepsy</article-title>. <source>Epilepsia</source> <volume>47</volume>: <fpage>185</fpage>–<lpage>192</lpage>.</citation>
</ref>
<ref id="bibr103-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vinten</surname><given-names>J.</given-names></name>
<name><surname>Bromley</surname><given-names>R.L.</given-names></name>
<name><surname>Taylor</surname><given-names>J.</given-names></name>
<name><surname>Adab</surname><given-names>N.</given-names></name>
<name><surname>Kini</surname><given-names>U.</given-names></name>
<name><surname>Baker</surname><given-names>G.A.</given-names></name>
</person-group> (<year>2009</year>) <article-title>The behavioral consequences of exposure to antiepileptic drugs in utero</article-title>. <source>Epilepsy Behav</source> <volume>14</volume>: <fpage>197</fpage>–<lpage>201</lpage>.</citation>
</ref>
<ref id="bibr104-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wide</surname><given-names>K.</given-names></name>
<name><surname>Hening</surname><given-names>E.</given-names></name>
<name><surname>Tomson</surname><given-names>T.</given-names></name>
<name><surname>Winbladh</surname><given-names>B.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Psychomotor development in preschool children exposed to antiepileptic drugs in utero</article-title>. <source>Acta Paediatr</source> <volume>91</volume>: <fpage>409</fpage>–<lpage>414</lpage>.</citation>
</ref>
<ref id="bibr105-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wikner</surname><given-names>B.N.</given-names></name>
<name><surname>Stiller</surname><given-names>C.O.</given-names></name>
<name><surname>Bergman</surname><given-names>U.</given-names></name>
<name><surname>Asker</surname><given-names>C.</given-names></name>
<name><surname>Källén</surname><given-names>B.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations</article-title>. <source>Pharmacoepidemiol Drug Saf</source> <volume>16</volume>: <fpage>1203</fpage>–<lpage>1210</lpage>.</citation>
</ref>
<ref id="bibr106-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wong</surname><given-names>W.T.</given-names></name>
<name><surname>Wong</surname><given-names>R.O.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Changing specificity of neurotransmitter regulation of rapid dendritic remodeling during synaptogenesis</article-title>. <source>Nat Neurosci</source> <volume>4</volume>: <fpage>351</fpage>–<lpage>352</lpage>.</citation>
</ref>
<ref id="bibr107-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wyszynski</surname><given-names>D.F.</given-names></name>
<name><surname>Nambisan</surname><given-names>M.</given-names></name>
<name><surname>Surve</surname><given-names>T.</given-names></name>
<name><surname>Alsdorf</surname><given-names>R.M.</given-names></name>
<name><surname>Smith</surname><given-names>C.R.</given-names></name>
<name><surname>Holmes</surname><given-names>L.B.</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Increased rate of major malformations in offspring exposed to valproate during pregnancy</article-title>. <source>Neurology</source> <volume>64</volume>: <fpage>961</fpage>–<lpage>965</lpage>.</citation>
</ref>
<ref id="bibr108-2042098611433192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yerby</surname><given-names>M.S.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Quality of life, epilepsy advances, and the evolving role of anticonvulsants in women with epilepsy</article-title>. <source>Neurology</source> <volume>55</volume>: <fpage>S23</fpage>–<lpage>S31</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>